Catalent (CTLT) 10-Q 12 Jun 23 2023 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Mar. 31, 2023	Apr. 30, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2023
Document Transition Report	false
Entity File Number	001-36587
Entity Registrant Name	Catalent, Inc.
Entity Incorporation, State or Country Code	DE
Entity Address, State or Province	NJ
Entity Tax Identification Number	20-8737688
Entity Address, Address Line One	14 Schoolhouse Road
Entity Address, City or Town	Somerset,
Entity Address, Postal Zip Code	08873
City Area Code	(732)
Local Phone Number	537-6200
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Title of 12(b) Security	Common Stock
Trading Symbol	CTLT
Security Exchange Name	NYSE
Amendment Flag	false
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Entity Central Index Key	0001596783
Current Fiscal Year End Date	--06-30
Entity Common Stock, Shares Outstanding (shares)		180,271,741

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Net revenue		$ 1,037	$ 1,273	$ 3,208	$ 3,515
Cost of sales		857	850	2,383	2,363
Gross margin		180	423	825	1,152
Selling, general, and administrative expenses		190	207	612	618
Payments for (Proceeds from) Businesses and Interest in Affiliates	[1]	0	0	0	(1)
Goodwill, Impairment Loss		210	0	210	0
Other Cost and Expense, Operating		15	5	40	25
Operating earnings		(235)	211	(37)	510
Interest expense, net		51	33	130	91
Other (income)/expense, net	[2]	(4)	2	(2)	25
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Total		(282)	176	(165)	394
Income tax expense		(55)	35	(19)	63
Net earnings/(loss)		(227)	141	(146)	331
Participating Securities, Distributed and Undistributed Earnings (Loss), Basic		0	0	0	15
Net Income (Loss) Available to Common Stockholders, Basic		$ (227)	$ 141	$ (146)	$ 316
Earnings Per Share, Basic		$ (1.26)	$ 0.78	$ (0.81)	$ 1.81
Earnings Per Share, Diluted		$ (1.26)	$ 0.78	$ (0.81)	$ 1.79
[1]Gain on sale of subsidiary for the nine months ended March 31, 2022[2]Other income (expense), net during the three and nine months ended March 31, 2023 and 2022 primarily includes foreign currency remeasurement losses/gains.

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income / (Loss) - USD ($) $ in Millions	3 Months Ended				9 Months Ended		12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2022
Other comprehensive income/(loss), net of tax
Net earnings/(loss)	$ (227)	$ 80	$ (5)	$ 141	$ (146)	$ 331	$ 499
Foreign currency translation adjustments	27			(22)	10	(54)
Pension and other post-retirement adjustments	0			1	0	2
Available for sale investments	2			(1)	4	(2)
Net change in derivatives and hedges, net of tax	(2)			17	12	21
Other comprehensive income/(loss), net of tax	27			(5)	26	(33)
Comprehensive income/(loss)	$ (200)	$ 199	$ (125)	$ 136	$ (120)	$ 298	$ 422

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Mar. 31, 2023	Jun. 30, 2022
Current assets:
Cash and cash equivalents	$ 252	$ 449
Trade receivables, net	1,049	1,051
Inventories	744	702
Prepaid expenses and other	693	626
Marketable Securities	0	89
Total current assets	2,738	2,917
Property, plant, and equipment, net	3,671	3,127
Other assets:
Goodwill	3,023	3,006
Other intangibles, net	1,012	1,060
Deferred Income Tax Assets, Net	42	49
Other Assets, Noncurrent	344	349
Total assets	10,830	10,508
Current Liabilities:
Debt, Current	588	31
Accounts payable	394	421
Other accrued liabilities	505	646
Total current liabilities	1,487	1,098
Long-term obligations, less current portion	4,261	4,171
Pension liability	104	103
Deferred Income Taxes	119	197
Other liabilities	156	164
Total liabilities	6,127	$ 5,733
Temporary Equity, Carrying Amount, Attributable to Parent	$ 0
Common Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01
Common Stock, Shares Authorized	1,000,000,000	1,000,000,000
Common Stock, Value, Outstanding	$ 2	$ 2
Preferred Stock, Value, Outstanding	0	0
Additional paid in capital	4,697	4,649
Accumulated deficit	372	518
Accumulated other comprehensive income/(loss)	(368)	(394)
Total shareholders' equity	4,703	4,775
Total liabilities, redeemable preferred stock, and shareholders’ equity	$ 10,830	$ 10,508
Common stock, shares issued (shares)	180,000,000	179,000,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Mar. 31, 2023	Jun. 30, 2022
Statement of Financial Position [Abstract]
Common Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01
Common Stock, Shares Authorized	1,000,000,000	1,000,000,000
Common stock, shares issued (shares)	180,000,000	179,000,000
Common Stock, Shares, Outstanding	180,000,000	179,000,000
Preferred Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01
Preferred Stock, Shares Authorized	100,000,000	100,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Accounts Receivable, Allowance for Credit Loss, Current	$ 29	$ 29
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	$ 1,540	$ 1,347

Consolidated Statement of Chang

Consolidated Statement of Changes in Shareholder's Equity - USD ($)	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income/(Loss)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Temporary Equity, Carrying Amount, Attributable to Parent	$ 359,000,000
Common Stock, Shares, Outstanding		170,549,000,000
Temporary Equity, Carrying Amount, Attributable to Parent	359,000,000
Beginning Balance at Jun. 30, 2021	3,915,000,000	$ 2,000,000	$ 4,205,000,000	$ 25,000,000	$ (317,000,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock Issued During Period, Value, Conversion of Convertible Securities	362,000,000		362,000,000
Stock-based compensation	42,000,000		42,000,000
Stock Issued During Period, Shares, Conversion of Convertible Securities		7,818,000,000
Cash paid, in lieu of equity, for tax withholding	(9,000,000)		(9,000,000)
APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition	9,000,000		9,000,000
Non-qualified stock	21,000,000		(21,000,000)
Dividends, Preferred Stock	6,000,000			(6,000,000)
Net earnings/(loss)	331,000,000			331,000,000
Other comprehensive income/(loss), net of tax	(33,000,000)				(33,000,000)
Ending Balance at Mar. 31, 2022	4,632,000,000	$ 2,000,000	4,630,000,000	350,000,000	(350,000,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture		780,000,000
Temporary Equity, Carrying Amount, Period Increase (Decrease)	(359,000,000)
Temporary Equity, Carrying Amount, Period Increase (Decrease)	(359,000,000)
Stock Issued During Period, Shares, Conversion of Convertible Securities		7,818,000,000
Beginning Balance at Jun. 30, 2021	3,915,000,000	$ 2,000,000	4,205,000,000	25,000,000	(317,000,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings/(loss)	499,000,000
Ending Balance at Jun. 30, 2022	4,775,000,000	$ 2,000,000	4,649,000,000	518,000,000	(394,000,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Temporary Equity, Carrying Amount, Attributable to Parent	0
Common Stock, Shares, Outstanding		179,050,000,000
Temporary Equity, Carrying Amount, Attributable to Parent	0
Beginning Balance at Dec. 31, 2021	4,481,000,000	$ 2,000,000	4,615,000,000	209,000,000	(345,000,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock Issued During Period, Value, Stock Options Exercised	0	0	0
Stock-based compensation	10,000,000		10,000,000
APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition	3,000,000		3,000,000
Non-qualified stock			(2,000,000)
Net earnings/(loss)	141,000,000			141,000,000
Other comprehensive income/(loss), net of tax	(5,000,000)				(5,000,000)
Ending Balance at Mar. 31, 2022	4,632,000,000	$ 2,000,000	4,630,000,000	350,000,000	(350,000,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share issuances related to stock-based compensation		97,000,000
Temporary Equity, Carrying Amount, Attributable to Parent	0
Common Stock, Shares, Outstanding		179,147,000,000
Temporary Equity, Carrying Amount, Attributable to Parent	$ 0
Common Stock, Shares, Outstanding	179,000,000	179,302,000,000
Beginning Balance at Jun. 30, 2022	$ 4,775,000,000	$ 2,000,000	4,649,000,000	518,000,000	(394,000,000)
Ending Balance at Dec. 31, 2022	4,892,000,000	2,000,000	4,686,000,000	599,000,000	(395,000,000)
Beginning Balance at Jun. 30, 2022	4,775,000,000	2,000,000	4,649,000,000	518,000,000	(394,000,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	35,000,000		35,000,000
Proceeds from Tax Withholding Obligations	0		(4,000,000)
APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition	9,000,000
APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition	4,000,000		9,000,000
Net earnings/(loss)	(146,000,000)			(146,000,000)
Other comprehensive income/(loss), net of tax	26,000,000				26,000,000
Ending Balance at Mar. 31, 2023	4,703,000,000	$ 2,000,000	4,697,000,000	372,000,000	(368,000,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture		855,000,000
Temporary Equity, Carrying Amount, Attributable to Parent	0
Common Stock, Shares, Outstanding		179,988,000,000
Temporary Equity, Carrying Amount, Attributable to Parent	0
Beginning Balance at Dec. 31, 2022	4,892,000,000	$ 2,000,000	4,686,000,000	599,000,000	(395,000,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Equity offering, sale of common stock,		0
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture	0
Stock-based compensation	6,000,000		6,000,000
APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition	2,000,000		2,000,000
APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition	3,000,000		3,000,000
Non-qualified stock	2,000,000
Net earnings/(loss)	(227,000,000)			(227,000,000)
Other comprehensive income/(loss), net of tax	27,000,000				27,000,000
Ending Balance at Mar. 31, 2023	4,703,000,000	$ 2,000,000	$ 4,697,000,000	$ 372,000,000	$ (368,000,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture		169,000,000
Temporary Equity, Carrying Amount, Attributable to Parent	$ 0
Common Stock, Shares, Outstanding	180,000,000	180,157,000,000
Temporary Equity, Carrying Amount, Attributable to Parent	$ 0

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions		3 Months Ended			6 Months Ended	9 Months Ended		12 Months Ended
		Mar. 31, 2023	Sep. 30, 2022	Mar. 31, 2022	Dec. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2022	Jun. 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net earnings/(loss)			$ (5)		$ 75	$ (146)	$ 331
Adjustments to reconcile earnings/(loss) from operations to net cash from operations:
Depreciation and amortization						308	278
Goodwill, Impairment Loss		$ 210		$ 0		210	0
Non-cash foreign currency transaction (gain)/loss, net						(6)	25
Restructuring and Related Cost, Incurred Cost						18	0
Amortization and write-off of debt financing costs						6	5
Asset impairments charges and (gain)/loss on sale of assets						4	21
Payments for (Proceeds from) Businesses and Interest in Affiliates	[1]	0		0		0	(1)
Debt Call Premium Fees						0	4
Derivative, Gain (Loss) on Derivative, Net						0	(2)
Share issuances related to stock-based compensation						35	42
Provision/(benefit) for deferred income taxes					(12)	(69)	13	$ 9
Provision for bad debts and inventory						99	14
Change in operating assets and liabilities:
Decrease/(increase) in trade receivables						18	60
Decrease/(increase) in inventories						(135)	(93)
Increase/(decrease) in accounts payable						(39)	(34)
Other assets/accrued liabilities, net — current and non-current			(150)		(174)	(245)	(293)	(423)
Net Cash Provided by (Used in) Operating Activities, Total						58	370
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of property and equipment and other productive assets						(455)	(425)
Proceeds from Sale and Maturity of Marketable Securities						(89)	(25)
Proceeds from Sale of Property, Plant, and Equipment						8	0
Settlement on sale of subsidiaries, net						0	3
Payment for acquisitions, net of cash acquired						(474)	(1,033)
Payments to Acquire Investments							4
Proceeds from Sale and Maturity of Other Investments						(2)
Net cash (used in) investing activities						(834)	(1,490)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from Issuance of Debt						715	1,100
Payments related to long-term obligations						(176)	(72)
Payments of Debt Issuance Costs						(4)	(15)
Dividends and Interest Paid						0	(4)
Proceeds from Tax Withholding Obligations						0
Cash paid, in lieu of equity, for tax withholding							(9)
Proceeds from (Repurchase of) Equity [Abstract]
Proceeds from Stock Options Exercised						4	21
Proceeds from (Payments for) Other Financing Activities						33	9
Net cash (used in)/provided by financing activities						572	1,030
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents						7	(20)
NET INCREASE/(DECREASE) IN CASH AND EQUIVALENTS						(197)	(110)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents		252		$ 786		252	786	449	$ 896
CASH AND EQUIVALENTS AT BEGINNING OF PERIOD			$ 449		$ 449	449
CASH AND EQUIVALENTS AT END OF PERIOD		$ 252				252		$ 449
SUPPLEMENTARY CASH FLOW INFORMATION:
Interest paid						145	93
Income taxes paid, net						83	40
Capital Expenditures Incurred but Not yet Paid						$ 8	$ 50
[1]Gain on sale of subsidiary for the nine months ended March 31, 2022

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	9 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Business Catalent, Inc. ( “ Catalent ” or the “ Company ” ) directly and wholly owns PTS Intermediate Holdings LLC ( “ Intermediate Holdings ” ). Intermediate Holdings directly and wholly owns Catalent Pharma Solutions, Inc. ( “ Operating Company ” ). The financial results of Catalent are comprised of the financial results of Operating Company and its subsidiaries on a consolidated basis. Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ( “U.S. GAAP ” ) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the nine months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the year ending June 30, 2023. The consolidated balance sheet at June 30, 2022 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. For further information on the Company's accounting policies and footnotes, refer to the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended June 30, 2022 (as amended by Amendment No.1 on Form 10-K/A filed with the Securities and Exchange Commission (the “SEC”) on June 12, 2023, the “Amended Fiscal 2022 10-K”). Reportable Segments Effective July 1, 2022, in connection with the appointment of a new President and Chief Executive Officer, the Company changed its operating structure and reorganized its executive leadership team accordingly. This new organizational structure includes simplifying the four operating and reportable segments the Company disclosed during fiscal 2022 to two: (i) Biologics and (ii) Pharma and Consumer Health. Set forth below is a summary description of the Company's two current operating and reportable segments. Biologics—The Biologics segment provides the same services as the Biologics segment the Company reported in fiscal 2022, with some organizational adjustments and the addition of analytical development and testing services for large molecules that were previously disclosed as part of the Company's prior Oral and Specialty Delivery segment. The Biologics segment as reorganized provides development and manufacturing for biologic proteins; cell, gene, and other nucleic acid therapies; plasmid DNA; induced pluripotent stem cells ( Pharma and Consumer Health—The Pharma and Consumer Health segment encompasses, except as noted above, the offerings of three of the Company's prior reportable segments—Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services—and comprises the Company’s market-leading capabilities for complex oral solids, softgel formulations, Zydis® fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms; formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms; and clinical trial development and supply services. Each segment reports through a separate management team and ultimately reports to the Company's President and Chief Executive Officer, who is designated as the Chief Operating Decision Maker for segment reporting purposes. The Company's operating segments are the same as its reportable segments. All prior-period comparative segment information has been recast retrospectively to reflect the current reportable segments in accordance with Accounting Standards Codification (“ASC”) 280, Segment Reporting , promulgated by the Financial Accounting Standards Board (the “FASB”). Revision of Previously Issued Financial Statements In connection with the preparation of its consolidated financial statements as of and for the three and nine months ended March 31, 2023, the Company identified an immaterial prior period error related to the recognition of revenue in its previously issued consolidated financial statements. In accordance with SAB No. 99, “Materiality,” and SAB No. 108, “Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements,” and as described further in Note 2, Revisions of Previously Issued Financial Statements , the Company evaluated the error and determined that the related impacts were not material to its financial statements for the prior annual period when they occurred, but that correcting the the error would be significant to the Company's results of operations for the three and nine months ended March 31, 2023. Accordingly, the Company has revised previously reported financial information for such immaterial error. A summary of revisions to certain previously reported financial information presented herein for comparative purposes is included in Note 2, Revisions of Previously Issued Financial Statements . Reclassifications Consequent to the reorganization noted above, certain prior-period amounts were reclassified to conform to the current period presentation. Foreign Currency Translation The financial statements of the Company’s operations are generally measured using the local currency as the functional currency. Adjustments to translate the assets and liabilities of operations outside the United States (“U.S.”) into U.S. dollars are accumulated as a component of other comprehensive income utilizing period-end exchange rates. Since July 1, 2018, the Company has accounted for its Argentine operations as highly inflationary. Concentrations of Credit Risk and Major Customers Concentration of credit risk, with respect to accounts receivable, is limited due to the large number of customers and their dispersion across different geographic areas. The customers are primarily concentrated in the pharmaceutical, biopharmaceutical and consumer products industries. The Company does not normally require collateral or any other security to support credit sales. The Company performs ongoing credit evaluations of its customers’ financial conditions and maintains reserves for credit losses. Such losses historically have been within the Company’s expectations. As of March 31, 2023 and June 30, 2022, the Company had one customer that represented 23% and 14%, respectively, of its aggregate net trade receivables and current contract asset values, primarily associated with the Company's Biologics segment. After performing a risk assessment of this customer, the Company has determined that a reserve is not warranted as of March 31, 2023. Additionally, the Company had two customers in its Biologics segment that each that represented approximately 11% of consolidated net revenue during the three months ended March 31, 2023. These same two customers represented 9% and 5% of net revenue in the three months ended March 31, 2022. Depreciation Depreciation expense was $72 million and $66 million for the three months ended March 31, 2023 and 2022, respectively. Depreciation expense was $207 million and $188 million for the nine months ended March 31, 2023 and 2022, respectively. Depreciation expense includes amortization of assets related to finance leases. The Company charges repairs and maintenance costs to expense as incurred. Amortization Amortization expense related to other intangible assets was $34 million and $33 million for the three months ended March 31, 2023 and 2022, respectively. Amortization expense related to other intangible assets was $101 million and $90 million for the nine months ended March 31, 2023 and 2022, respectively. Research and Development Costs The Company expenses research and development costs as incurred. Research and development costs amounted to $4 million and $6 million for the three months ended March 31, 2023 and 2022, respectively. Research and development costs amounted to $13 million and $18 million for the nine months ended March 31, 2023 and 2022, respectively. Marketable Securities The Company classifies its marketable securities as available-for-sale, because it may sell certain of its marketable securities prior to the stated maturity for various reasons, including management of liquidity, credit risk, duration, relative return, and asset allocation. The Company determines the fair value of each marketable security in its portfolio at each period end and recognizes gains and losses in the portfolio in other comprehensive income. As of March 31, 2023, all of the Company's outstanding marketable securities had matured. The amortized cost basis of all previously owned marketable securities approximated fair value and all previously outstanding marketable securities matured within one year. Recent Financial Accounting Standards New Accounting Standards Not Adopted as of March 31, 2023 In March 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting, which provides optional guidance to ease the potential burden in accounting for the discontinuation of a reference rate such as LIBOR, formerly known as the London Interbank Offered Rate, because of reference rate reform. In December 2022, the FASB issued ASU 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848, which delayed the effective date from December 31, 2022 to December 31, 2024. The Company is currently evaluating the impact of adopting this guidance on its consolidated financial statements.

Accounting Changes and Error Co

Accounting Changes and Error Corrections - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Jun. 30, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022
Accounting Changes and Error Corrections [Abstract]
REVISIONS OF PREVIOUSLY-ISSUED FINANCIAL STATEMENTS [Text Block]	REVISIONS OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS As described in the Amended Fiscal 2022 10-K, in preparing the consolidated financial statements for the three and nine months ended March 31, 2023, the Company identified a $26 million error related to the over-recognition of revenue in the consolidated financial statements it issued with respect to its fiscal year ended June 30, 2022. This error resulted from the misapplication of the contract modification guidance in accordance with ASC 606, Revenue from Contracts with Customers, related to one of the Company’s customer arrangements. The Company assessed the materiality of the error both quantitatively and qualitatively and determined this error to be immaterial to those consolidated financial statements. However, the Company concluded that the effect of correcting the error in the quarter ended March 31, 2023 would materially misstate the Company’s unaudited consolidated financial statements for the three and nine months ended March 31, 2023 and, accordingly, determined that it was necessary to revise the consolidated financial statements it previously issued with respect to the fiscal year ended June 30, 2022. The following tables reflect the impact of this revision on the Company’s consolidated balance sheet as of June 30, 2022: Consolidated Balance Sheet June 30, 2022 (Dollars in millions) As Previously Reported Adjustment As Revised Prepaid expenses and other $ 625 $ 1 $ 626 Total current assets 2,916 1 2,917 Total assets 10,507 1 10,508 Other accrued liabilities 620 26 646 Total current liabilities 1,072 26 1,098 Deferred income taxes 202 (5) 197 Total liabilities 5,712 21 5,733 Retained earnings 538 (20) 518 Total shareholders' equity 4,795 (20) 4,775 Total liabilities and shareholders' equity $ 10,507 $ 1 10,508
Other Accrued Liabilities		$ 646	$ 553	$ 484	$ 646

Business Combinations

Business Combinations	3 Months Ended
	Mar. 31, 2023
Business Combinations [Abstract]
Business Combination Disclosure [Text Block]	BUSINESS COMBINATIONS

Goodwill

Goodwill	9 Months Ended
	Mar. 31, 2023
Goodwill Disclosure [Abstract]
Goodwill	GOODWILL The following table summarizes the changes between June 30, 2022 and March 31, 2023 in the carrying amount of goodwill in total and by segment: (Dollars in millions) Biologics Pharma and Consumer Health Total Balance at June 30, 2022 (1) $ 1,535 $ 1,471 $ 3,006 Additions (2) — 216 216 Reallocation 16 (16) — Foreign currency translation adjustments 7 4 11 Impairment — (210) (210) Balance at March 31, 2023 $ 1,558 $ 1,465 $ 3,023 (1) As of result of the organizational realignments effective July 1, 2022, (described in Note 1, Basis of Presentation and Summary of Significant Accounting Policies ), the beginning balance presentation has been reclassified to conform with the current period reportable segments. All changes as a result of the organizational realignments are captured in the row labeled "reallocation." (2) The addition to goodwill is a result of the Metrics acquisition. For further details, see Note 4, Business Combinations. As part of the business reorganization discussed in Note 1, Basis of Presentation and Summary of Significant Accounting Policies , the goodwill from the previous Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services segments was reallocated between the current Biologics and Pharma and Consumer Health segments. Goodwill Impairment Charges The Company assessed the current and future economic outlook as of March 31, 2023 for its reporting units in its Pharma and Consumer Health and Biologics segments and identified an indicator for impairment of the goodwill previously recorded for one of the reporting units in its Pharma and Consumer Health segment. The evaluation began with a qualitative assessment of each reporting unit to determine if it was more likely than not that the fair value of the reporting unit was less than its carrying value. The qualitative assessment did not indicate that it was more likely than not that the fair value exceeded the carrying value in its Consumer Health reporting unit, which led to a quantitative assessment for each of the Company's reporting units. The Company estimated the fair value of its reporting units using a combination of the income and market approaches. In performing the goodwill impairment test, the Company used a long-term revenue growth rate of 3% and discount rates ranging from 9% to 10.50% in its estimation of fair value. The evaluation performed resulted in an impairment charge of $210 million with respect to the Consumer Health reporting unit.

Earnings Per Share

Earnings Per Share	9 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Earnings Per Share	EARNINGS PER SHARE Effective as of the first quarter of fiscal 2023, the Company computes earnings per share of the Company’s common stock, par value $0.01 (the “Common Stock”) using the treasury stock method. Prior to fiscal 2023, the Company computed earnings (loss) per share of the Common Stock using the two-class method required due to the participating nature of the previously outstanding Series A Preferred Stock (as defined and discussed in Note 14, Equity and Accumulated Other Comprehensive Loss ). Diluted net (loss) earnings per share is computed using the weighted average number of shares of Common Stock outstanding plus the weighted average number of shares of Common Stock that would be issued assuming exercise or conversion of all potentially dilutive instruments. Dilutive securities having an anti-dilutive effect on diluted net earnings per share are excluded from the calculation. The dilutive effect of the securities that are issuable under the Company’s equity incentive plans are reflected in diluted earnings per share by application of the treasury stock method. Prior to fiscal 2023, the Company applied the if-converted method to compute the potentially dilutive effect of the previously outstanding Series A Preferred Stock. The reconciliations between basic and diluted earnings per share attributable to Catalent common shareholders for the three and nine months ended March 31, 2023 and 2022, respectively, are as follows: Three Months Ended Nine Months Ended (In millions except per share data) 2023 2022 2023 2022 Net (loss) earnings $ (227) $ 141 $ (146) $ 331 Less: Net earnings attributable to preferred shareholders — — — (15) Net (loss) earnings attributable to common shareholders $ (227) $ 141 $ (146) $ 316 Weighted average shares outstanding - basic 181 180 180 176 Weighted average dilutive securities issuable - stock plans — 1 — 1 Weighted average shares outstanding - diluted 181 181 180 177 (Loss) earnings per share: Basic $ (1.26) $ 0.78 $ (0.81) $ 1.81 Diluted $ (1.26) $ 0.78 $ (0.81) $ 1.79 The Company's formerly outstanding Series A Preferred Stock was deemed a participating security, meaning that it had the right to participate in undistributed earnings with the Company's Common Stock. On November 23, 2020, the holders of Series A Preferred Stock converted 265,223 shares of Series A Preferred Stock and $2 million of unpaid accrued dividends into shares of Common Stock. On November 18, 2021, the holders of Series A Preferred Stock converted the remaining 384,777 shares of Series A Preferred Stock and $2 million of unpaid accrued dividends into shares of Common Stock. Shares with an antidilutive effect on the weighted average shares outstanding for the three and nine months ended March 31, 2023 and 2022 were not material.

Other (Income)_ Expense, Net

Other (Income)/ Expense, Net	9 Months Ended
	Mar. 31, 2023
Other Income and Expenses [Abstract]
Other Income and Other Expense Disclosure [Text Block]	OTHER (INCOME) EXPENSE, NET The components of other expense, net for the three and nine months ended March 31, 2023 and 2022 are as follows: Three Months Ended Nine Months Ended (Dollars in millions) 2023 2022 2023 2022 Debt financing costs (1) $ — $ — $ — $ 4 Foreign currency (gains) losses (2) (4) 4 (5) 28 Other (3) — (2) 3 (7) Total other (income) expense, net $ (4) $ 2 $ (2) $ 25 (1) Debt financing costs for the nine months ended March 31, 2022 includes $4 million of financing charges related to the $450 million aggregate principal amount of U.S. dollar-denominated term loans borrowed in that period under the Company’s senior secured credit facilities (together with all of the remaining U.S. dollar-denominated term loans outstanding, the “Term B-3 Loans”). (2) Foreign currency remeasurement gains/losses include both cash and non-cash transactions.

Derivative Instruments and Hedg

Derivative Instruments and Hedging Activities	9 Months Ended
	Mar. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities	DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES Risk Management Objective of Using Derivatives The Company is exposed to fluctuations in the currency exchange rates applicable to its investments in operations outside the U.S. While the Company does not actively hedge against changes in foreign currency, the Company has mitigated exposure from its investments in its European operations by denominating a portion of its debt in euros. At March 31, 2023, the Company had euro-denominated debt outstanding of $895 million (U.S. dollar equivalent), which is designated and qualifies as a hedge against its net investment in its European operations. For non-derivatives designated and qualifying as net investment hedges, the effective portion of translation gains or losses are reported in accumulated other comprehensive loss as part of the cumulative translation adjustment. The unhedged portions of the euro-denominated debt translation gains or losses are reported in the consolidated statements of operations. The following table summarizes net investment hedge activity during the three and nine months ended March 31, 2023 and 2022. Three Months Ended Nine Months Ended (Dollars in millions) 2023 2022 2023 2022 Unrealized foreign exchange gain (loss) within other comprehensive income $ (16) $ 28 $ (20) $ 90 Unrealized foreign exchange gain (loss) within statement of operations $ — $ — $ — $ (11) The net accumulated gain on the instrument designated as a hedge as of March 31, 2023 within other comprehensive loss was approximately $107 million. Amounts are reclassified out of accumulated other comprehensive loss into earnings when the entity to which the gains and losses relate is either sold or substantially liquidated. Interest-Rate Swap In April 2020, pursuant to its interest rate and risk management strategy, the Company entered into an interest-rate swap agreement with Bank of America N.A. (the “2020 Rate Swap”) as a hedge against the economic effect of a portion of the variable interest obligation associated with its U.S. dollar-denominated term loans under its senior secured credit facilities. In February 2021, in connection with an amendment to the Credit Agreement, the Company paid $2 million in cash to Bank of America N.A to settle the 2020 Rate Swap. This loss is deferred in stockholders’ equity, net of income taxes, as a component of accumulated other comprehensive loss, and amortized as an adjustment to interest expense, net over the original term of the formerly outstanding term loans. The net amount of deferred losses on cash flow hedges that is expected to be reclassified from accumulated other comprehensive loss into interest expense, net within the next twelve months is not material. In February 2021, the Company entered into a new interest-rate swap agreement with Bank of America N.A. (the “2021 Rate Swap”) as a hedge against the economic effect of a portion of the variable interest obligation associated with its Term B-3 Loans. The 2021 Rate Swap effectively fixed the rate of interest payable on that portion of the Term B-3 Loans, thereby reducing the impact of future interest rate changes on future interest expense. As a result of the 2021 Rate Swap, the variable portion of the applicable interest rate on $500 million of the Term B-3 Loans is now effectively fixed at 0.9985%. The 2021 Rate Swap qualifies for and is designated as a cash-flow hedge. The Company evaluates hedge effectiveness at the inception of the hedge and on an ongoing basis. The cash flows associated with the 2021 Rate Swap is reported in cash provided by operating activities in the consolidated statements of cash flows. The unrealized gain recorded in stockholder's equity from marking the 2021 Rate Swap to market during the nine months ended March 31, 2023 was $15 million. A summary of the estimated fair value of the 2021 Rate Swap reported in the consolidated balance sheets is stated in the table below: March 31, 2023 June 30, 2022 (Dollars in millions) Balance Sheet Classification Estimated Fair Value Balance Sheet Classification Estimated Fair Value Interest-rate swap Other long-term assets $ 51 Other long-term assets $ 36

Fair Value Measures and Disclos

Fair Value Measures and Disclosures	9 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Fair Value Disclosures	FAIR VALUE MEASUREMENTS ASC 820, Fair Value Measurement, defines fair value as the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. Valuation techniques used to measure fair value should maximize the use of observable inputs and minimize the use of unobservable inputs. To measure fair value, the Company uses the following fair value hierarchy based on three levels of inputs, of which Level 1 and Level 2 are considered observable and Level 3 is considered unobservable: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data by correlation or other means. Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Value is determined using pricing models, discounted cash flow methodologies, or similar techniques and also includes instruments for which the determination of fair value requires significant judgment or estimation. Assets and Liabilities Measured at Fair Value on a Recurring Basis The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses of the Company approximate fair value based on the short maturities of these instruments. The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level of classification as of the end of each reporting period. The following table sets forth the Company’s financial assets and liabilities that were measured at fair value on a recurring basis and the fair value measurement for such assets and liabilities at March 31, 2023 and June 30, 2022: (Dollars in millions) Basis of Fair Value Measurement March 31, 2023 Total Level 1 Level 2 Level 3 Assets: Interest-rate swap $ 51 $ — $ 51 $ — Trading securities 1 1 — — June 30, 2022 Assets: Marketable securities $ 89 $ 89 $ — $ — Interest-rate swap 36 — 36 — Trading securities 2 2 — — The fair value of the 2021 Rate Swap is determined at the end of each reporting period based on valuation models that use interest rate yield curves and discount rates as inputs. The discount rates are based on U.S. deposit or U.S. Treasury rates. The significant inputs used in the valuation models are readily available in public markets or can be derived from observable market transactions, and the valuation is therefore classified as Level 2 in the fair-value hierarchy. Long-lived assets, goodwill, and other intangible assets are subject to non-recurring fair value measurement for the evaluation of potential impairment. T he carrying value of the Consumer Health reporting unit approximates its fair value as of March 31, 2023 following the impairment charge .

Income Taxes

Income Taxes	9 Months Ended
	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES The Company accounts for income taxes in accordance with ASC 740, Income Taxes . Generally, fluctuations in the effective tax rate are due to changes in relative amounts of U.S. and non-U.S. pretax income, the tax impact of special items, and other discrete tax items. Discrete items include, but are not limited to, changes in non-U.S. statutory tax rates, amortization of certain assets, changes in the Company’s reserve for uncertain tax positions, and tax impact of certain equity compensation. In the normal course of business, the Company is subject to examination by taxing authorities around the world. The Company is presently under audit in select jurisdictions in the United States and in Europe, but no material impact is expected to the financial results once these audits are completed. ASC 740 provides guidance for the accounting of uncertain income tax positions recognized in the Company's tax filings. This guidance provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that, based on technical merits, the position will be sustained upon examination, including resolution of any related appeal or litigation process. As of March 31, 2023 and June 30, 2022, the Company’s reserve against uncertain income tax positions was $2 million and $5 million, respectively. The reduction during the quarter is attributable both the favorable settlement of an international audit examination and the expiration of the statute of limitations on certain of the reserves. Interest and penalties related to uncertain tax positions are recognized as a component of income tax expense. The Company recorded a benefit for income taxes for the three months ended March 31, 2023 of $55 million relative to loss before income taxes of $282 million. The Company recorded a provision for income taxes for the three months ended March 31, 2022 of $35 million relative to earnings before income taxes of $176 million. The income tax benefit for the quarter is primarily the result of a deferred tax benefit resulting from the impairment of goodwill during the quarter and certain discrete income tax benefits. This income tax benefit was partially reduced by unfavorable permanent tax adjustments that were fixed and not impacted by the reduced pretax earnings. Discrete items recognized during the quarter include a favorable audit settlement and equity related compensation tax benefits. The quarterly provision was also impacted by the geographic distribution of the Company's pretax income resulting from our business mix, changes in the tax impact of permanent differences, restructuring, special items, certain equity related compensation, and other discrete tax items that may have unique tax implications depending on the nature of the item.

Employee Retirement Benefit Pla

Employee Retirement Benefit Plans	9 Months Ended
	Mar. 31, 2023
Retirement Benefits [Abstract]
Employee Retirement Benefit Plans	EMPLOYEE RETIREMENT BENEFIT PLANS Components of the Company’s net periodic benefit costs are as follows: Three Months Ended Nine Months Ended (Dollars in millions) 2023 2022 2023 2022 Components of net periodic benefit cost: Selling, general, and administrative expenses: Service cost $ 1 $ 1 $ 3 $ 3 Other expense, net: Interest cost 3 1 7 3 Expected return on plan assets (2) (2) (6) (7) Amortization (1) — 1 — 3 Net amount recognized $ 2 $ 1 $ 4 $ 2 (1) Amount represents the amortization of unrecognized actuarial losses.

Equity and Accumulated Other Co

Equity and Accumulated Other Comprehensive Income (Loss)	9 Months Ended
	Mar. 31, 2023
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Equity, Redeemable Preferred Stock and Accumulated Other Comprehensive Loss	EQUITY AND ACCUMULATED OTHER COMPREHENSIVE LOSS Description of Capital Stock The Company is authorized to issue 1.00 billion shares of its Common Stock and 100 million shares of preferred stock, par value $0.01 per share. In accordance with the Company’s amended and restated certificate of incorporation, each share of Common Stock has one vote, and the Common Stock votes together as a single class. In 2019, the Company designated 1,000,000 shares of its preferred stock, par value $0.01, as its Series A Convertible Preferred Stock (the “Series A Preferred Stock”) and issued and sold 650,000 shares of the Series A Preferred Stock to affiliates of Leonard Green & Partners, L.P. In November 2021, the holders of the Series A Preferred Stock converted all then-outstanding shares of Series A Preferred Stock and $2 million of related unpaid accrued dividends into shares of Common Stock. Accumulated Other Comprehensive Loss The components of the changes in the cumulative translation adjustment, derivatives and hedges, minimum pension liability, and marketable securities for the three and nine months ended March 31, 2023 and 2022 are presented below. Three Months Ended Nine Months Ended (Dollars in millions) 2023 2022 2023 2022 Foreign currency translation adjustments: Net investment hedge $ (16) $ 28 $ (20) $ 90 Long-term intercompany loans 9 (8) (1) (15) Translation adjustments 31 (36) 26 (109) Total foreign currency translation adjustment, pretax 24 (16) 5 (34) Tax (benefit) expense (3) 6 (5) 20 Total foreign currency translation adjustment, net of tax $ 27 $ (22) $ 10 $ (54) Net change in derivatives and hedges: Net (loss) gain recognized during the period $ (3) $ 23 $ 15 $ 28 Total derivatives and hedges, pretax (3) 23 15 28 Tax (benefit) expense (1) 6 3 7 Net change in derivatives and hedges, net of tax $ (2) $ 17 $ 12 $ 21 Net change in minimum pension liability: Net gain recognized during the period $ — $ 1 $ — $ 2 Total pension liability, pretax — 1 — 2 Tax benefit — — — — Net change in minimum pension liability, net of tax $ — $ 1 $ — $ 2 Net change in marketable securities: Net gain (loss) recognized during the period $ — $ (2) $ 1 $ (3) Amounts reclassified from accumulated other 2 — 4 — Net change in marketable securities, pretax 2 (2) 5 (3) Tax (benefit) expense — $ (1) 1 $ (1) Net change in marketable securities, net of tax $ 2 $ (1) $ 4 $ (2) For the three months ended March 31, 2023 and 2022, the changes in accumulated other comprehensive loss, net of tax by component are as follows: (Dollars in millions) Foreign Exchange Translation Adjustments Pension and Liability Adjustments Derivatives and Hedges Marketable Securities Other Total Balance at December 31, 2022 $ (395) $ (38) $ 41 $ (2) $ (1) $ (395) Other comprehensive income (loss) before 27 — (2) — — 25 Amounts reclassified from accumulated other — — — 2 — 2 Net current period other comprehensive income (loss) 27 — (2) 2 — 27 Balance at March 31, 2023 $ (368) $ (38) $ 39 $ — $ (1) $ (368) (Dollars in millions) Foreign Exchange Translation Adjustments Pension and Liability Adjustments Derivatives and Hedges Marketable Securities Other Total Balance at December 31, 2021 $ (300) $ (46) $ 4 $ (2) $ (1) $ (345) Other comprehensive (loss) income before (22) — 17 (1) — (6) Amounts reclassified from accumulated other — 1 — — — 1 Net current period other comprehensive (loss) income (22) 1 17 (1) — (5) Balance at March 31, 2022 $ (322) $ (45) $ 21 $ (3) $ (1) $ (350) For the nine months ended March 31, 2023 and 2022, the changes in accumulated other comprehensive loss, net of tax by component are as follows: (Dollars in millions) Foreign Exchange Translation Adjustments Pension and Liability Adjustments Derivatives and Hedges Marketable Securities Other Total Balance at June 30, 2022 $ (378) $ (38) $ 27 $ (4) $ (1) $ (394) Other comprehensive income before 10 — 12 — — 22 Amounts reclassified from accumulated other — — — 4 — 4 Net current period other comprehensive income 10 — 12 4 — 26 Balance at March 31, 2023 $ (368) $ (38) $ 39 $ — $ (1) $ (368)

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	COMMITMENTS AND CONTINGENCIES Litigation From time to time, the Company may be involved in legal proceedings arising in the ordinary course of business, including, without limitation, inquiries and claims concerning environmental contamination as well as litigation and allegations in connection with acquisitions, product liability, manufacturing or packaging defects, and claims for reimbursement for the cost of lost or damaged active pharmaceutical ingredients, the cost of any of which could be significant. Such matters are inherently uncertain, and there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter will not have a material adverse effect upon the Company’s consolidated financial statements. The Company records a liability in its consolidated financial statements for these matters when a loss is known or considered probable and the amount can be reasonably estimated. The Company reviews these estimates each accounting period as additional information is known and adjusts the loss provision when appropriate. If a matter is both probable to result in a liability and the amount of loss can be reasonably estimated, the Company estimates and discloses the possible loss or range of loss to the extent necessary for its consolidated financial statements not to be misleading. If the loss is not probable or cannot be reasonably estimated, a liability is not recorded in the Company's consolidated financial statements. Any legal or other expenses associated with the litigation are accrued for as the expenses are incurred. The Company intends to vigorously defend itself against any such litigation and does not currently believe that the outcome of any such litigation will have a material adverse effect on the Company’s consolidated financial statements. In addition, the healthcare industry is highly regulated and government agencies continue to scrutinize certain practices affecting government programs and otherwise. City of Warwick Retirement System Class Action In February 2023, an alleged shareholder filed a Complaint styled City of Warwick Retirement System v. Catalent, Inc., et al. , No. 23-cv-01108 in New Jersey federal court against the Company and three of its then-officers (collectively, the “Defendants”) purportedly on behalf of a putative “class” consisting of persons who purchased or otherwise acquired Company securities between August 30, 2021 and October 31, 2022, inclusive (the “Class Period”). The Complaint asserts claims under Section 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended and the related regulations, alleging that, unbeknownst to investors, Defendants purportedly engaged in accounting and channel stuffing schemes to pad Catalent’s revenues and failed to disclose adverse facts that purportedly were known to or recklessly disregarded by Defendants. Specifically, the Complaint alleges that (i) Catalent overstated revenue and earnings by prematurely recognizing revenue in violation of U.S. GAAP; (ii) Catalent had material weaknesses in its internal controls over financial reporting related to revenue recognition; (iii) Catalent falsely represented demand for its products while it knowingly sold more product to its direct customers than could be sold to healthcare providers and end consumers; (iv) Catalent cut corners on safety and control procedures at key production facilities; (v) Catalent disregarded regulatory rules at key production facilities in order to rapidly produce excess inventory that was used to pad the Company’s financial results through premature revenue recognition in violation of U.S. GAAP or stuffing its direct customers with this excess inventory; and (vi) Defendants lacked a reasonable basis for their positive statements about the Company’s financial performance, outlook, and regulatory compliance during the Class Period. The Company believes that the allegations and claims set forth in the Complaint are without merit and intends to vigorously defend itself once the court names a lead plaintiff and the lead plaintiff files or designates an operative complaint. Subpoenas and Requests for Information

Segment Information

Segment Information	9 Months Ended
	Mar. 31, 2023
Segment Reporting [Abstract]
Segment Information	SEGMENT INFORMATION The Company evaluates the performance of its segments based on segment earnings before other (expense) income, impairments, restructuring costs, interest expense, income tax expense, and depreciation and amortization (“Segment EBITDA”). Segment EBITDA is subject to important limitations. These consolidated financial statements include information concerning Segment EBITDA (a) because Segment EBITDA is an operational measure used by management in the assessment of the operating segments, the allocation of resources to the segments, and the setting of strategic goals and annual goals for the segments, and (b) in order to provide supplemental information that the Company considers relevant for the readers of the consolidated financial statements. The Company’s presentation of Segment EBITDA may not be comparable to similarly titled measures used by other companies. The following tables include Segment EBITDA for each of the Company's current reportable segments during the three and nine months ended March 31, 2023 and 2022: (Dollars in millions) Three Months Ended Nine Months Ended 2023 2022 2023 2022 Segment EBITDA reconciled to net (loss) earnings: Biologics $ 6 $ 218 $ 299 $ 584 Pharma and Consumer Health 125 144 368 390 Sub-Total $ 131 $ 362 $ 667 $ 974 Reconciling items to net earnings Unallocated costs (1) (256) (54) (394) (211) Depreciation and amortization (106) (99) (308) (278) Interest expense, net (51) (33) (130) (91) Income tax expense 55 (35) 19 (63) Net (loss) earnings $ (227) $ 141 $ (146) $ 331 (1) Unallocated costs include restructuring and special items, stock-based compensation, gain on sale of subsidiary, impairment charges, certain other corporate directed costs, and other costs that are not allocated to the segments as follows: (Dollars in millions) Three Months Ended March 31, Nine Months Ended 2023 2022 2023 2022 Impairment charges and gain/loss on sale of assets (a) $ (6) $ (2) $ (4) $ (21) Stock-based compensation (6) (10) (35) (42) Restructuring and other special items (b) (17) (12) (59) (43) Goodwill impairment charges (c) (210) — (210) — Gain on sale of subsidiary (d) — — — 1 Other income (expense), net (e) 4 (2) 2 (25) Unallocated corporate costs, net (21) (28) (88) (81) Total unallocated costs $ (256) $ (54) $ (394) $ (211) (a) Impairment charges and gain/loss on sale of assets during the nine months ended March 31, 2022 include fixed asset impairment charges associated with a product the Company no longer manufactures in its Pharma and Consumer Health segment. (b) Restructuring and other special items during the three months ended March 31, 2023 include (i) restructuring charges associated with plans to reduce costs, consolidate facilities, and optimize our infrastructure across the organization and (ii) transaction and integration costs associated with the Metrics acquisition. Restructuring and other special items for the nine months ended March 31, 2023 also includes warehouse exit costs for a product the Company no longer manufactures in its Pharma and Consumer Health segment. For further details on restructuring charges, see Note 9, Restructuring Costs . Restructuring and other special items during the three months ended March 31, 2022 include (i) integration costs primarily associated with the Bettera Wellness acquisition and (ii) unrealized losses on venture capital investments. Restructuring and other special items during the nine months ended March 31, 2022 also include transaction and integration costs associated with the Delphi Genetics S.A., Hepatic Cell Therapy Support S.A., RheinCell Therapeutics GmbH acquisitions and the Acorda Therapeutics, Inc. transaction. (c) Goodwill impairment charges during the three and nine months ended March 31, 2023 was associated with the Company’s Consumer Health reporting unit. For further details, see Note 5, Goodwill . (d) Gain on sale of subsidiary for the nine months ended March 31, 2022 was due to the sale of the Company’s facility in Woodstock, Illinois and the associated business. (e) Other income (expense), net during the three and nine months ended March 31, 2023 and 2022 primarily includes foreign currency remeasurement losses/gains. The following table includes total assets for each segment, as well as reconciling items necessary to total the amounts reported in the consolidated financial statements. (Dollars in millions) March 31, June 30, Assets: Biologics $ 5,904 $ 5,770 Pharma and Consumer Health 4,847 4,356 Corporate and eliminations 79 382 Total assets $ 10,830 $ 10,508

Supplemental Balance Sheet Info

Supplemental Balance Sheet Information	9 Months Ended
	Mar. 31, 2023
Balance Sheet Related Disclosures [Abstract]
Supplemental Balance Sheet Information	SUPPLEMENTAL BALANCE SHEET INFORMATION Supplemental balance sheet information at March 31, 2023 and June 30, 2022 is detailed in the following tables. Inventories Work-in-process and inventories include raw materials, labor, and overhead. Total inventories consist of the following: (Dollars in millions) March 31, June 30, Raw materials and supplies $ 762 $ 651 Work-in-process 144 109 Total inventories, gross 906 760 Inventory cost adjustment (1) (162) (58) Total inventories $ 744 $ 702 (1) Increase in inventory cost adjustment is primarily associated with inventory write-offs resulting from the terminations of certain take-or-pay arrangements. Prepaid expenses and other Prepaid expenses and other consist of the following: (Dollars in millions) March 31, June 30, Prepaid expenses $ 70 $ 61 Short-term contract assets 488 398 Spare parts supplies 24 22 Prepaid income tax 35 27 Non-U.S. value-added tax 35 48 Other current assets 41 70 Total prepaid expenses and other $ 693 $ 626 Other accrued liabilities Other accrued liabilities consist of the following: (Dollars in millions) March 31, June 30, Contract liabilities $ 203 $ 211 Accrued employee-related expenses 132 198 Accrued expenses 111 140 Operating lease liabilities 11 14 Restructuring accrual 1 1 Accrued interest 24 32 Accrued income tax 23 50 Total other accrued liabilities $ 505 $ 646

Subsequent Events (Notes)

Subsequent Events (Notes)	9 Months Ended
	Mar. 31, 2023
Subsequent Events [Abstract]
Subsequent Events [Text Block]	SUBSEQUENT EVENTS

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ( “U.S. GAAP ” ) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the nine months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the year ending June 30, 2023. The consolidated balance sheet at June 30, 2022 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. For further information on the Company's accounting policies and footnotes, refer to the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended June 30, 2022 (as amended by Amendment No.1 on Form 10-K/A filed with the Securities and Exchange Commission (the “SEC”) on June 12, 2023, the “Amended Fiscal 2022 10-K”). Reportable Segments Effective July 1, 2022, in connection with the appointment of a new President and Chief Executive Officer, the Company changed its operating structure and reorganized its executive leadership team accordingly. This new organizational structure includes simplifying the four operating and reportable segments the Company disclosed during fiscal 2022 to two: (i) Biologics and (ii) Pharma and Consumer Health. Set forth below is a summary description of the Company's two current operating and reportable segments. Biologics—The Biologics segment provides the same services as the Biologics segment the Company reported in fiscal 2022, with some organizational adjustments and the addition of analytical development and testing services for large molecules that were previously disclosed as part of the Company's prior Oral and Specialty Delivery segment. The Biologics segment as reorganized provides development and manufacturing for biologic proteins; cell, gene, and other nucleic acid therapies; plasmid DNA; induced pluripotent stem cells ( Pharma and Consumer Health—The Pharma and Consumer Health segment encompasses, except as noted above, the offerings of three of the Company's prior reportable segments—Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services—and comprises the Company’s market-leading capabilities for complex oral solids, softgel formulations, Zydis® fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms; formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms; and clinical trial development and supply services. Each segment reports through a separate management team and ultimately reports to the Company's President and Chief Executive Officer, who is designated as the Chief Operating Decision Maker for segment reporting purposes. The Company's operating segments are the same as its reportable segments. All prior-period comparative segment information has been recast retrospectively to reflect the current reportable segments in accordance with Accounting Standards Codification (“ASC”) 280, Segment Reporting , promulgated by the Financial Accounting Standards Board (the “FASB”).
Reclassification, Policy	Reclassifications Consequent to the reorganization noted above, certain prior-period amounts were reclassified to conform to the current period presentation.
Foreign Currency Translation	Foreign Currency Translation The financial statements of the Company’s operations are generally measured using the local currency as the functional currency. Adjustments to translate the assets and liabilities of operations outside the United States (“U.S.”) into U.S. dollars are accumulated as a component of other comprehensive income utilizing period-end exchange rates. Since July 1, 2018, the Company has accounted for its Argentine operations as highly inflationary.
Concentration Risk, Credit Risk, Policy	Concentrations of Credit Risk and Major Customers Concentration of credit risk, with respect to accounts receivable, is limited due to the large number of customers and their dispersion across different geographic areas. The customers are primarily concentrated in the pharmaceutical, biopharmaceutical and consumer products industries. The Company does not normally require collateral or any other security to support credit sales. The Company performs ongoing credit evaluations of its customers’ financial conditions and maintains reserves for credit losses. Such losses historically have been within the Company’s expectations. As of March 31, 2023 and June 30, 2022, the Company had one customer that represented 23% and 14%, respectively, of its aggregate net trade receivables and current contract asset values, primarily associated with the Company's Biologics segment. After performing a risk assessment of this customer, the Company has determined that a reserve is not warranted as of March 31, 2023. Additionally, the Company had two customers in its Biologics segment that each that represented approximately 11% of consolidated net revenue during the three months ended March 31, 2023. These same two customers represented 9% and 5% of net revenue in the three months ended March 31, 2022.
Depreciation, Depletion, and Amortization	Depreciation Depreciation expense was $72 million and $66 million for the three months ended March 31, 2023 and 2022, respectively. Depreciation expense was $207 million and $188 million for the nine months ended March 31, 2023 and 2022, respectively. Depreciation expense includes amortization of assets related to finance leases. The Company charges repairs and maintenance costs to expense as incurred. Amortization Amortization expense related to other intangible assets was $34 million and $33 million for the three months ended March 31, 2023 and 2022, respectively. Amortization expense related to other intangible assets was $101 million and $90 million for the nine months ended March 31, 2023 and 2022, respectively.
Research and Development Costs	Research and Development Costs The Company expenses research and development costs as incurred. Research and development costs amounted to $4 million and $6 million for the three months ended March 31, 2023 and 2022, respectively. Research and development costs amounted to $13 million and $18 million for the nine months ended March 31, 2023 and 2022, respectively.
Marketable Securities	Marketable Securities The Company classifies its marketable securities as available-for-sale, because it may sell certain of its marketable securities prior to the stated maturity for various reasons, including management of liquidity, credit risk, duration, relative return, and asset allocation. The Company determines the fair value of each marketable security in its portfolio at each period end and recognizes gains and losses in the portfolio in other comprehensive income. As of March 31, 2023, all of the
Recent Financial Accounting Standards	Recent Financial Accounting Standards New Accounting Standards Not Adopted as of March 31, 2023 In March 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting, which provides optional guidance to ease the potential burden in accounting for the discontinuation of a reference rate such as LIBOR, formerly known as the London Interbank Offered Rate, because of reference rate reform. In December 2022, the FASB issued ASU 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848, which delayed the effective date from December 31, 2022 to December 31, 2024. The Company is currently evaluating the impact of adopting this guidance on its consolidated financial statements.

Revenue Recognition (Tables)

Revenue Recognition (Tables) - USD ($) $ in Millions	3 Months Ended			9 Months Ended		12 Months Ended
	Mar. 31, 2023	Sep. 30, 2022	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2022
Disaggregation of Revenue [Line Items]
Net revenue	$ 1,037	$ 1,015	$ 1,273	$ 3,208	$ 3,515	$ 4,802
Elimination of revenue attributable to multiple locations	(33)		(27)	$ (94)	(85)
Revenue Recognition and Deferred Revenue [Abstract]
Contractual Liabilities				The contract liabilities balances (current and non-current) as of March 31, 2023 and June 30, 2022 are as follows: (Dollars in millions) Balance at June 30, 2022 $ 220 Balance at March 31, 2023 $ 212 Revenue recognized in the period from amounts included in contracts liability at the beginning of the period: $ (120)
Geographical [Member]
Disaggregation of Revenue [Line Items]
Disaggregation of Revenue				The following table allocates revenue by the location where the goods were made or the service performed: Three Months Ended Nine Months Ended (Dollars in millions) 2023 2022 2023 2022 United States $ 685 $ 847 $ 2,117 $ 2,270 Europe $ 306 373 936 1,095 Other $ 79 80 249 235 Elimination of revenue attributable to multiple locations $ (33) (27) (94) (85) Total $ 1,037 $ 1,273 $ 3,208 $ 3,515
United States
Disaggregation of Revenue [Line Items]
Net revenue	685		847	$ 2,117	2,270
Europe
Disaggregation of Revenue [Line Items]
Net revenue	306		373	936	1,095
International Other
Disaggregation of Revenue [Line Items]
Net revenue	$ 79		$ 80	$ 249	$ 235
Product and Service[Member]
Disaggregation of Revenue [Line Items]
Disaggregation of Revenue				The following tables reflect net revenue for the three and nine months ended March 31, 2023 and 2022, by type of activity and reportable segment (in millions): Three Months Ended March 31, 2023 Biologics Pharma and Consumer Health Total Manufacturing & commercial product supply $ 133 $ 349 $ 482 Development services & clinical supply (1) 342 214 556 Total $ 475 $ 563 $ 1,038 Inter-segment revenue elimination (1) Combined net revenue $ 1,037 Three Months Ended March 31, 2022 Biologics Pharma and Consumer Health Total Manufacturing & commercial product supply $ 200 $ 368 $ 568 Development services & clinical supply 500 206 706 Total $ 700 $ 574 $ 1,274 Inter-segment revenue elimination (1) Combined net revenue $ 1,273 Nine Months Ended March 31, 2023 Biologics Pharma and Consumer Health Total Manufacturing & commercial product supply $ 303 $ 1,027 $ 1,330 Development services & clinical supply (1) 1,275 605 1,880 Total $ 1,578 $ 1,632 $ 3,210 Inter-segment revenue elimination (2) Combined net revenue $ 3,208 Nine Months Ended March 31, 2022 Biologics Pharma and Consumer Health Total Manufacturing & commercial product supply $ 503 $ 1,042 $ 1,545 Development services & clinical supply 1,386 587 1,973 Total $ 1,889 $ 1,629 $ 3,518 Inter-segment revenue elimination (3) Combined net revenue $ 3,515

Goodwill (Tables)

Goodwill (Tables)	9 Months Ended
	Mar. 31, 2023
Goodwill Disclosure [Abstract]
Goodwill - Rollforward	The following table summarizes the changes between June 30, 2022 and March 31, 2023 in the carrying amount of goodwill in total and by segment: (Dollars in millions) Biologics Pharma and Consumer Health Total Balance at June 30, 2022 (1) $ 1,535 $ 1,471 $ 3,006 Additions (2) — 216 216 Reallocation 16 (16) — Foreign currency translation adjustments 7 4 11 Impairment — (210) (210) Balance at March 31, 2023 $ 1,558 $ 1,465 $ 3,023 (1) As of result of the organizational realignments effective July 1, 2022, (described in Note 1, Basis of Presentation and Summary of Significant Accounting Policies ), the beginning balance presentation has been reclassified to conform with the current period reportable segments. All changes as a result of the organizational realignments are captured in the row labeled "reallocation." (2) The addition to goodwill is a result of the Metrics acquisition. For further details, see Note 4, Business Combinations. As part of the business reorganization discussed in Note 1, Basis of Presentation and Summary of Significant Accounting Policies , the goodwill from the previous Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services segments was reallocated between the current Biologics and Pharma and Consumer Health segments. Goodwill Impairment Charges The Company assessed the current and future economic outlook as of March 31, 2023 for its reporting units in its Pharma and Consumer Health and Biologics segments and identified an indicator for impairment of the goodwill previously recorded for one of the reporting units in its Pharma and Consumer Health segment. The evaluation began with a qualitative assessment of each reporting unit to determine if it was more likely than not that the fair value of the reporting unit was less than its carrying value. The qualitative assessment did not indicate that it was more likely than not that the fair value exceeded the carrying value in its Consumer Health reporting unit, which led to a quantitative assessment for each of the Company's reporting units. The Company estimated the fair value of its reporting units using a combination of the income and market approaches. In performing the goodwill impairment test, the Company used a long-term revenue growth rate of 3% and discount rates ranging from 9% to 10.50% in its estimation of fair value. The evaluation performed resulted in an impairment charge of $210 million with respect to the Consumer Health reporting unit.

Long-Term Obligations and Other

Long-Term Obligations and Other Short-Term Borrowings (Tables)	3 Months Ended	9 Months Ended
	Mar. 31, 2023	Mar. 31, 2023
Debt Disclosure [Abstract]
Long-Term Obligations, Presented Net of Issue Discounts and Fees Paid to Lenders, and Other Short-Term Borrowings	Long-term obligations and short-term borrowings consisted of the following at March 31, 2023 and June 30, 2022: (Dollars in millions) Maturity March 31, 2023 June 30, 2022 Senior secured credit facilities Term loan facility B-3 (6.813% as of March 31, 2023) February 2028 $ 1,422 $ 1,433 Revolving credit facility (1) (7.538% as of March 31, 2023) November 2027 550 — 5.000% senior notes due 2027 July 2027 500 500 2.375% Euro senior notes due 2028 (2) March 2028 895 874 3.125% senior notes due 2029 February 2029 550 550 3.500% senior notes due 2030 April 2030 650 650 Financing lease obligations 2023 to 2038 297 234 Other obligations (3) 2023 to 2028 26 2 Unamortized discount and debt issuance costs (41) (41) Total debt $ 4,849 $ 4,202 Less: current portion of long-term obligations and other short-term borrowings (1) 588 31 Long-term obligations, less current portion $ 4,261 $ 4,171 (1) During the nine months ended March 31, 2023, the Company drew down $715 million on its revolving credit facility to supplement operating cash flows and fund the Metrics acquisition, of which $165 million was repaid during the nine months ended March 31, 2023. The Company has elected to classify the borrowing on its revolving credit facility as current as it intends to repay a portion of the borrowing using cash flows from operations and/or refinance the borrowing within the next twelve months. (2) The change in the carrying value of this euro-denominated debt was due to fluctuations in foreign currency exchange rates. (3) The increase in other obligations is associated with $24 million in proceeds from a failed sale-leaseback transaction that occurred in the three months ended March 31, 2023.
Fair Value Disclosures [Abstract]
Schedule Of Carrying And Fair Value Of Financial Instruments Table		The carrying amounts and the estimated fair values of the Company’s principal categories of debt as of March 31, 2023 and June 30, 2022 are as follows: March 31, 2023 June 30, 2022 (Dollars in millions) Fair Value Measurement Carrying Value Estimated Fair Value Carrying Value Estimated Fair Value 5.000% senior notes due 2027 Level 2 $ 500 $ 493 $ 500 $ 483 2.375% Euro senior notes due 2028 Level 2 895 823 874 744 3.125% senior notes due 2029 Level 2 550 500 550 476 3.500% senior notes due 2030 Level 2 650 598 650 561 Senior secured credit facilities & other Level 2 2,295 2,079 1,669 1,575 Subtotal $ 4,890 $ 4,493 $ 4,243 $ 3,839 Unamortized discount and debt issuance (41) — (41) — Total debt $ 4,849 $ 4,493 $ 4,202 $ 3,839

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The reconciliations between basic and diluted earnings per share attributable to Catalent common shareholders for the three and nine months ended March 31, 2023 and 2022, respectively, are as follows: Three Months Ended Nine Months Ended (In millions except per share data) 2023 2022 2023 2022 Net (loss) earnings $ (227) $ 141 $ (146) $ 331 Less: Net earnings attributable to preferred shareholders — — — (15) Net (loss) earnings attributable to common shareholders $ (227) $ 141 $ (146) $ 316 Weighted average shares outstanding - basic 181 180 180 176 Weighted average dilutive securities issuable - stock plans — 1 — 1 Weighted average shares outstanding - diluted 181 181 180 177 (Loss) earnings per share: Basic $ (1.26) $ 0.78 $ (0.81) $ 1.81 Diluted $ (1.26) $ 0.78 $ (0.81) $ 1.79
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	antidilutive effect on the weighted average shares outstanding for the three and nine months ended March 31, 2023 and 2022 were not material.

Other Income and Expense (Table

Other Income and Expense (Tables)	9 Months Ended
	Mar. 31, 2023
Other Income and Expenses [Abstract]
Schedule of Other Nonoperating Income (Expense)	The components of other expense, net for the three and nine months ended March 31, 2023 and 2022 are as follows: Three Months Ended Nine Months Ended (Dollars in millions) 2023 2022 2023 2022 Debt financing costs (1) $ — $ — $ — $ 4 Foreign currency (gains) losses (2) (4) 4 (5) 28 Other (3) — (2) 3 (7) Total other (income) expense, net $ (4) $ 2 $ (2) $ 25 (1) Debt financing costs for the nine months ended March 31, 2022 includes $4 million of financing charges related to the $450 million aggregate principal amount of U.S. dollar-denominated term loans borrowed in that period under the Company’s senior secured credit facilities (together with all of the remaining U.S. dollar-denominated term loans outstanding, the “Term B-3 Loans”). (2) Foreign currency remeasurement gains/losses include both cash and non-cash transactions.

Derivative Instruments and He_2

Derivative Instruments and Hedging Activities Net Investment Hedge Activity (Tables)	9 Months Ended
	Mar. 31, 2023
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Schedule of Net Investment Hedge in Accumulated Other Comprehensive Income (Loss) and Statement of Financial Performance	The following table summarizes net investment hedge activity during the three and nine months ended March 31, 2023 and 2022. Three Months Ended Nine Months Ended (Dollars in millions) 2023 2022 2023 2022 Unrealized foreign exchange gain (loss) within other comprehensive income $ (16) $ 28 $ (20) $ 90 Unrealized foreign exchange gain (loss) within statement of operations $ — $ — $ — $ (11)
Schedule of Interest Rate Derivatives	A summary of the estimated fair value of the 2021 Rate Swap reported in the consolidated balance sheets is stated in the table below: March 31, 2023 June 30, 2022 (Dollars in millions) Balance Sheet Classification Estimated Fair Value Balance Sheet Classification Estimated Fair Value Interest-rate swap Other long-term assets $ 51 Other long-term assets $ 36

Fair Value Measures and Discl_2

Fair Value Measures and Disclosures (Tables)	9 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table sets forth the Company’s financial assets and liabilities that were measured at fair value on a recurring basis and the fair value measurement for such assets and liabilities at March 31, 2023 and June 30, 2022: (Dollars in millions) Basis of Fair Value Measurement March 31, 2023 Total Level 1 Level 2 Level 3 Assets: Interest-rate swap $ 51 $ — $ 51 $ — Trading securities 1 1 — — June 30, 2022 Assets: Marketable securities $ 89 $ 89 $ — $ — Interest-rate swap 36 — 36 — Trading securities 2 2 — —

Employee Retirement Benefit P_2

Employee Retirement Benefit Plans (Tables)	9 Months Ended
	Mar. 31, 2023
Retirement Benefits [Abstract]
Components of Company's Net Periodic Benefit Costs	Components of the Company’s net periodic benefit costs are as follows: Three Months Ended Nine Months Ended (Dollars in millions) 2023 2022 2023 2022 Components of net periodic benefit cost: Selling, general, and administrative expenses: Service cost $ 1 $ 1 $ 3 $ 3 Other expense, net: Interest cost 3 1 7 3 Expected return on plan assets (2) (2) (6) (7) Amortization (1) — 1 — 3 Net amount recognized $ 2 $ 1 $ 4 $ 2 (1) Amount represents the amortization of unrecognized actuarial losses.

Equity and Accumulated Other _2

Equity and Accumulated Other Comprehensive Income (Loss) (Tables)	9 Months Ended
	Mar. 31, 2023
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Schedule of Comprehensive Income (Loss)	Accumulated Other Comprehensive Loss The components of the changes in the cumulative translation adjustment, derivatives and hedges, minimum pension liability, and marketable securities for the three and nine months ended March 31, 2023 and 2022 are presented below. Three Months Ended Nine Months Ended (Dollars in millions) 2023 2022 2023 2022 Foreign currency translation adjustments: Net investment hedge $ (16) $ 28 $ (20) $ 90 Long-term intercompany loans 9 (8) (1) (15) Translation adjustments 31 (36) 26 (109) Total foreign currency translation adjustment, pretax 24 (16) 5 (34) Tax (benefit) expense (3) 6 (5) 20 Total foreign currency translation adjustment, net of tax $ 27 $ (22) $ 10 $ (54) Net change in derivatives and hedges: Net (loss) gain recognized during the period $ (3) $ 23 $ 15 $ 28 Total derivatives and hedges, pretax (3) 23 15 28 Tax (benefit) expense (1) 6 3 7 Net change in derivatives and hedges, net of tax $ (2) $ 17 $ 12 $ 21 Net change in minimum pension liability: Net gain recognized during the period $ — $ 1 $ — $ 2 Total pension liability, pretax — 1 — 2 Tax benefit — — — — Net change in minimum pension liability, net of tax $ — $ 1 $ — $ 2 Net change in marketable securities: Net gain (loss) recognized during the period $ — $ (2) $ 1 $ (3) Amounts reclassified from accumulated other 2 — 4 — Net change in marketable securities, pretax 2 (2) 5 (3) Tax (benefit) expense — $ (1) 1 $ (1) Net change in marketable securities, net of tax $ 2 $ (1) $ 4 $ (2)
Schedule of Accumulated Other Comprehensive Income (Loss)	For the three months ended March 31, 2023 and 2022, the changes in accumulated other comprehensive loss, net of tax by component are as follows: (Dollars in millions) Foreign Exchange Translation Adjustments Pension and Liability Adjustments Derivatives and Hedges Marketable Securities Other Total Balance at December 31, 2022 $ (395) $ (38) $ 41 $ (2) $ (1) $ (395) Other comprehensive income (loss) before 27 — (2) — — 25 Amounts reclassified from accumulated other — — — 2 — 2 Net current period other comprehensive income (loss) 27 — (2) 2 — 27 Balance at March 31, 2023 $ (368) $ (38) $ 39 $ — $ (1) $ (368) (Dollars in millions) Foreign Exchange Translation Adjustments Pension and Liability Adjustments Derivatives and Hedges Marketable Securities Other Total Balance at December 31, 2021 $ (300) $ (46) $ 4 $ (2) $ (1) $ (345) Other comprehensive (loss) income before (22) — 17 (1) — (6) Amounts reclassified from accumulated other — 1 — — — 1 Net current period other comprehensive (loss) income (22) 1 17 (1) — (5) Balance at March 31, 2022 $ (322) $ (45) $ 21 $ (3) $ (1) $ (350) For the nine months ended March 31, 2023 and 2022, the changes in accumulated other comprehensive loss, net of tax by component are as follows: (Dollars in millions) Foreign Exchange Translation Adjustments Pension and Liability Adjustments Derivatives and Hedges Marketable Securities Other Total Balance at June 30, 2022 $ (378) $ (38) $ 27 $ (4) $ (1) $ (394) Other comprehensive income before 10 — 12 — — 22 Amounts reclassified from accumulated other — — — 4 — 4 Net current period other comprehensive income 10 — 12 4 — 26 Balance at March 31, 2023 $ (368) $ (38) $ 39 $ — $ (1) $ (368)

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Mar. 31, 2023
Segment Reporting [Abstract]
Reconciliation of Earnings/(Loss) from Continuing Operations to EBITDA	(Dollars in millions) Three Months Ended Nine Months Ended 2023 2022 2023 2022 Segment EBITDA reconciled to net (loss) earnings: Biologics $ 6 $ 218 $ 299 $ 584 Pharma and Consumer Health 125 144 368 390 Sub-Total $ 131 $ 362 $ 667 $ 974 Reconciling items to net earnings Unallocated costs (1) (256) (54) (394) (211) Depreciation and amortization (106) (99) (308) (278) Interest expense, net (51) (33) (130) (91) Income tax expense 55 (35) 19 (63) Net (loss) earnings $ (227) $ 141 $ (146) $ 331 (1) Unallocated costs include restructuring and special items, stock-based compensation, gain on sale of subsidiary, impairment charges, certain other corporate directed costs, and other costs that are not allocated to the segments as follows: (Dollars in millions) Three Months Ended March 31, Nine Months Ended 2023 2022 2023 2022 Impairment charges and gain/loss on sale of assets (a) $ (6) $ (2) $ (4) $ (21) Stock-based compensation (6) (10) (35) (42) Restructuring and other special items (b) (17) (12) (59) (43) Goodwill impairment charges (c) (210) — (210) — Gain on sale of subsidiary (d) — — — 1 Other income (expense), net (e) 4 (2) 2 (25) Unallocated corporate costs, net (21) (28) (88) (81) Total unallocated costs $ (256) $ (54) $ (394) $ (211) (a) Impairment charges and gain/loss on sale of assets during the nine months ended March 31, 2022 include fixed asset impairment charges associated with a product the Company no longer manufactures in its Pharma and Consumer Health segment. (b) Restructuring and other special items during the three months ended March 31, 2023 include (i) restructuring charges associated with plans to reduce costs, consolidate facilities, and optimize our infrastructure across the organization and (ii) transaction and integration costs associated with the Metrics acquisition. Restructuring and other special items for the nine months ended March 31, 2023 also includes warehouse exit costs for a product the Company no longer manufactures in its Pharma and Consumer Health segment. For further details on restructuring charges, see Note 9, Restructuring Costs . Restructuring and other special items during the three months ended March 31, 2022 include (i) integration costs primarily associated with the Bettera Wellness acquisition and (ii) unrealized losses on venture capital investments. Restructuring and other special items during the nine months ended March 31, 2022 also include transaction and integration costs associated with the Delphi Genetics S.A., Hepatic Cell Therapy Support S.A., RheinCell Therapeutics GmbH acquisitions and the Acorda Therapeutics, Inc. transaction. (c) Goodwill impairment charges during the three and nine months ended March 31, 2023 was associated with the Company’s Consumer Health reporting unit. For further details, see Note 5, Goodwill . (d) Gain on sale of subsidiary for the nine months ended March 31, 2022 was due to the sale of the Company’s facility in Woodstock, Illinois and the associated business.
Total Assets for Each Segment and Reconciling in Consolidated Financial Statements	The following table includes total assets for each segment, as well as reconciling items necessary to total the amounts reported in the consolidated financial statements. (Dollars in millions) March 31, June 30, Assets: Biologics $ 5,904 $ 5,770 Pharma and Consumer Health 4,847 4,356 Corporate and eliminations 79 382 Total assets $ 10,830 $ 10,508

Supplemental Balance Sheet In_2

Supplemental Balance Sheet Information (Tables)	9 Months Ended
	Mar. 31, 2023
Balance Sheet Related Disclosures [Abstract]
Inventory	Inventories Work-in-process and inventories include raw materials, labor, and overhead. Total inventories consist of the following: (Dollars in millions) March 31, June 30, Raw materials and supplies $ 762 $ 651 Work-in-process 144 109 Total inventories, gross 906 760 Inventory cost adjustment (1) (162) (58) Total inventories $ 744 $ 702
Prepaid and Other Assets	Prepaid expenses and other Prepaid expenses and other consist of the following: (Dollars in millions) March 31, June 30, Prepaid expenses $ 70 $ 61 Short-term contract assets 488 398 Spare parts supplies 24 22 Prepaid income tax 35 27 Non-U.S. value-added tax 35 48 Other current assets 41 70 Total prepaid expenses and other $ 693 $ 626
Other Accrued Liabilities	Other accrued liabilities Other accrued liabilities consist of the following: (Dollars in millions) March 31, June 30, Contract liabilities $ 203 $ 211 Accrued employee-related expenses 132 198 Accrued expenses 111 140 Operating lease liabilities 11 14 Restructuring accrual 1 1 Accrued interest 24 32 Accrued income tax 23 50 Total other accrued liabilities $ 505 $ 646

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies Research and Development Expense (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Research and Development Expense [Abstract]
Research and Development Costs			Research and Development Costs The Company expenses research and development costs as incurred. Research and development costs amounted to $4 million and $6 million for the three months ended March 31, 2023 and 2022, respectively. Research and development costs amounted to $13 million and $18 million for the nine months ended March 31, 2023 and 2022, respectively.
Research and Development Expense	$ 4	$ 6	$ 13	$ 18

Basis of Presentation and Sum_4

Basis of Presentation and Summary of Significant Accounting Policies Concentrations of Credit Risk and Major Customers (Details)	9 Months Ended
	Mar. 31, 2023 Rate	Mar. 31, 2022	Jun. 30, 2022 Rate
Fair Value, Concentration of Risk, Financial Assets, Balance Sheet Groupings [Abstract]
Concentration Risk, Credit Risk, Policy	Concentrations of Credit Risk and Major Customers Concentration of credit risk, with respect to accounts receivable, is limited due to the large number of customers and their dispersion across different geographic areas. The customers are primarily concentrated in the pharmaceutical, biopharmaceutical and consumer products industries. The Company does not normally require collateral or any other security to support credit sales. The Company performs ongoing credit evaluations of its customers’ financial conditions and maintains reserves for credit losses. Such losses historically have been within the Company’s expectations. As of March 31, 2023 and June 30, 2022, the Company had one customer that represented 23% and 14%, respectively, of its aggregate net trade receivables and current contract asset values, primarily associated with the Company's Biologics segment. After performing a risk assessment of this customer, the Company has determined that a reserve is not warranted as of March 31, 2023. Additionally, the Company had two customers in its Biologics segment that each that represented approximately 11% of consolidated net revenue during the three months ended March 31, 2023. These same two customers represented 9% and 5% of net revenue in the three months ended March 31, 2022.
Percentage, trade receivables and current contract asset values, Net	23%		14%
Segment Reporting, Disclosure of Major Customers	11	9
Segment Reporting, Disclosure of Major Customer		5%

Basis of Presentation and Sum_5

Basis of Presentation and Summary of Significant Accounting Polices Depreciation (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Depreciation, Depletion and Amortization [Abstract]
Depreciation, Depletion, and Amortization			Depreciation Depreciation expense was $72 million and $66 million for the three months ended March 31, 2023 and 2022, respectively. Depreciation expense was $207 million and $188 million for the nine months ended March 31, 2023 and 2022, respectively. Depreciation expense includes amortization of assets related to finance leases. The Company charges repairs and maintenance costs to expense as incurred. Amortization Amortization expense related to other intangible assets was $34 million and $33 million for the three months ended March 31, 2023 and 2022, respectively. Amortization expense related to other intangible assets was $101 million and $90 million for the nine months ended March 31, 2023 and 2022, respectively.
Depreciation Cost	$ 72	$ 66	$ 207	$ 188

Accounting Changes and Error _2

Accounting Changes and Error Corrections (Details) - USD ($)	3 Months Ended						6 Months Ended		9 Months Ended		12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Dec. 31, 2022	Dec. 31, 2021	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2021
Accounting Changes and Error Corrections [Abstract]
Other Accrued Liabilities		$ 553,000,000	$ 484,000,000				$ 553,000,000				$ 646,000,000	$ 646,000,000
Total current liabilities	$ 1,487,000,000	1,552,000,000	969,000,000				1,552,000,000		$ 1,487,000,000		1,098,000,000	1,098,000,000
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Other Accrued Liabilities		553,000,000	484,000,000				553,000,000				646,000,000	646,000,000
Total current liabilities	1,487,000,000	1,552,000,000	969,000,000				1,552,000,000		1,487,000,000		1,098,000,000	1,098,000,000
Total liabilities	6,127,000,000	6,256,000,000	5,526,000,000				6,256,000,000		6,127,000,000		5,733,000,000	5,733,000,000
Retained earnings (Accumulated Deficit)		599,000,000					599,000,000
Accumulated deficit	372,000,000		518,000,000						372,000,000		518,000,000	518,000,000
Equity, Attributable to Parent	4,703,000,000	4,892,000,000	4,680,000,000				4,892,000,000		4,703,000,000		4,775,000,000	4,775,000,000
Prepaid expenses and other	693,000,000	715,000,000	633,000,000				715,000,000		693,000,000		626,000,000	626,000,000
Assets, Current	2,738,000,000	2,919,000,000	2,699,000,000				2,919,000,000		2,738,000,000		2,917,000,000	2,917,000,000
Deferred Income Tax Assets, Net	42,000,000								42,000,000		49,000,000
Assets	10,830,000,000	11,148,000,000	10,206,000,000				11,148,000,000		10,830,000,000		10,508,000,000	10,508,000,000
Liabilities and Equity	10,830,000,000	11,148,000,000	10,206,000,000				11,148,000,000		10,830,000,000		10,508,000,000	10,508,000,000
Net revenue	1,037,000,000		1,015,000,000	$ 1,273,000,000					3,208,000,000	$ 3,515,000,000	4,802,000,000
Gross margin	180,000,000		251,000,000	423,000,000					825,000,000	1,152,000,000	1,614,000,000
Operating earnings	(235,000,000)		53,000,000	211,000,000					(37,000,000)	510,000,000	730,000,000
Deferred Tax Liabilities, Gross	119,000,000	216,000,000	208,000,000				216,000,000		119,000,000		197,000,000
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	(282,000,000)		(4,000,000)	176,000,000					(165,000,000)	394,000,000	579,000,000
Income tax expense(benefit)	(55,000,000)	34,000,000	1,000,000	35,000,000					(19,000,000)	63,000,000	80,000,000
Net earnings/(loss)	(227,000,000)	$ 80,000,000	$ (5,000,000)	141,000,000					(146,000,000)	331,000,000	499,000,000
Participating Securities, Distributed and Undistributed Earnings (Loss), Basic	0			0					0	(15,000,000)
Net Income (Loss) Available to Common Stockholders, Basic	$ (227,000,000)			$ 141,000,000					$ (146,000,000)	$ 316,000,000	$ 483,000,000
Earnings Per Share, Basic	$ (1.26)	$ 440,000	$ (0.03)	$ 0.78					$ (0.81)	$ 1.81	$ 2.74
Earnings Per Share, Diluted	$ (1.26)		$ (0.03)	$ 0.78					$ (0.81)	$ 1.79	$ 2.73
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	$ (200,000,000)	$ 199,000,000	$ (125,000,000)	$ 136,000,000					$ (120,000,000)	$ 298,000,000	$ 422,000,000
Net earnings/(loss)			(5,000,000)				75,000,000		(146,000,000)	331,000,000
Provision/(benefit) for deferred income taxes							12,000,000		69,000,000	(13,000,000)	(9,000,000)
Other assets/accrued liabilities, net — current and non-current			(150,000,000)				(174,000,000)		(245,000,000)	(293,000,000)	(423,000,000)
Net cash provided by operating activities									58,000,000	370,000,000
Net Cash Provided by (Used in) Investing Activities									(834,000,000)	(1,490,000,000)
Net Cash Provided by (Used in) Financing Activities									572,000,000	1,030,000,000
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect									(197,000,000)	(110,000,000)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	252,000,000			786,000,000					252,000,000	786,000,000	449,000,000		$ 896,000,000
Stock Issued During Period, Value, Conversion of Convertible Securities										362,000,000
Share issuances related to stock-based compensation									35,000,000	42,000,000
Cash paid, in lieu of equity, for tax withholding										9,000,000
Proceeds from Stock Options Exercised									(4,000,000)	(21,000,000)
APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition	2,000,000			3,000,000					9,000,000
Dividends, Preferred Stock										6,000,000
Other Comprehensive Income (Loss), Net of Tax	27,000,000			(5,000,000)					26,000,000	(33,000,000)
Inventories	744,000,000								744,000,000		702,000,000
Inter-segment revenue elimination	(1,000,000)	(1,000,000)	0	(1,000,000)	$ (1,000,000)	$ (1,000,000)	(1,000,000)	$ (2,000,000)	(2,000,000)	(3,000,000)
Revenue		1,149,000,000	1,022,000,000		1,217,000,000	1,025,000,000	2,171,000,000	2,242,000,000
Cost of sales	857,000,000			850,000,000					2,383,000,000	2,363,000,000
Deferred Tax Liabilities, Tax Deferred Income												197,000,000
Total liabilities	6,127,000,000	6,256,000,000	5,526,000,000				6,256,000,000		6,127,000,000		5,733,000,000	5,733,000,000
Accumulated deficit	372,000,000		518,000,000						372,000,000		518,000,000	518,000,000
Equity, Attributable to Parent	4,703,000,000	4,892,000,000	4,680,000,000				4,892,000,000		4,703,000,000		4,775,000,000	4,775,000,000
Inventories	744,000,000								744,000,000		702,000,000
Biologics
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Assets	5,904,000,000								5,904,000,000		5,770,000,000
Net revenue	475,000,000			700,000,000					1,578,000,000	1,889,000,000
Revenue		580,000,000	523,000,000		641,000,000	548,000,000	1,103,000,000	1,189,000,000
Biologics | Manufacturing & Commercial Product Supply
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue	133,000,000			200,000,000					303,000,000	503,000,000
Revenue		75,000,000	94,000,000		169,000,000	134,000,000	169,000,000	303,000,000
Biologics | Development Services
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue	342,000,000			500,000,000					1,275,000,000	1,386,000,000
Revenue		505,000,000	429,000,000		472,000,000	414,000,000	934,000,000	886,000,000
PharmaConsumerHealth
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Assets	4,847,000,000								4,847,000,000		4,356,000,000
Net revenue	563,000,000			574,000,000					1,632,000,000	1,629,000,000
Revenue		570,000,000	499,000,000		577,000,000	478,000,000	1,069,000,000	1,055,000,000
PharmaConsumerHealth | Manufacturing & Commercial Product Supply
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue	349,000,000			368,000,000					1,027,000,000	1,042,000,000
Revenue		364,000,000	314,000,000		381,000,000	293,000,000	678,000,000	674,000,000
PharmaConsumerHealth | Development Services
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue	214,000,000			206,000,000					605,000,000	587,000,000
Revenue		206,000,000			196,000,000	185,000,000	391,000,000	381,000,000
Total Catalent before inter-segment revenue elimination
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue	1,038,000,000			1,274,000,000					3,210,000,000	3,518,000,000
Revenue		1,150,000,000	1,022,000,000		1,218,000,000	1,026,000,000	2,172,000,000	2,244,000,000
Total Catalent before inter-segment revenue elimination | Manufacturing & Commercial Product Supply
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue	482,000,000			568,000,000					1,330,000,000	1,545,000,000
Revenue		439,000,000	408,000,000		550,000,000	427,000,000	847,000,000	977,000,000
Total Catalent before inter-segment revenue elimination | Development Services
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue	$ 556,000,000			$ 706,000,000					$ 1,880,000,000	$ 1,973,000,000
Revenue		711,000,000			$ 668,000,000	$ 599,000,000	1,325,000,000	$ 1,267,000,000
Previously Reported
Accounting Changes and Error Corrections [Abstract]
Other Accrued Liabilities		527,000,000	458,000,000				527,000,000				620,000,000	620,000,000
Total current liabilities		1,526,000,000	943,000,000				1,526,000,000				1,072,000,000	1,072,000,000
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Other Accrued Liabilities		527,000,000	458,000,000				527,000,000				620,000,000	620,000,000
Total current liabilities		1,526,000,000	943,000,000				1,526,000,000				1,072,000,000	1,072,000,000
Total liabilities		6,235,000,000	5,505,000,000				6,235,000,000				5,712,000,000	5,712,000,000
Accumulated deficit		619,000,000	538,000,000				619,000,000				538,000,000	538,000,000
Equity, Attributable to Parent		4,912,000,000	4,700,000,000				4,912,000,000				4,795,000,000	4,795,000,000
Prepaid expenses and other		714,000,000	632,000,000				714,000,000				625,000,000	625,000,000
Assets, Current		2,918,000,000	2,698,000,000				2,918,000,000				2,916,000,000	2,916,000,000
Assets		11,147,000,000	10,205,000,000				11,147,000,000				10,507,000,000	10,507,000,000
Liabilities and Equity		11,147,000,000	10,205,000,000				11,147,000,000				10,507,000,000
Net revenue			1,022,000,000				2,171,000,000				4,828,000,000
Gross margin			258,000,000				645,000,000				1,640,000,000
Operating earnings			60,000,000				198,000,000				756,000,000
Deferred Tax Liabilities, Gross		221,000,000	214,000,000				221,000,000				202,000,000	202,000,000
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest			3,000,000				117,000,000				605,000,000
Income tax expense(benefit)		33,000,000	3,000,000				36,000,000				86,000,000
Net earnings/(loss)		$ 81,000,000	$ 0				$ 81,000,000				519,000,000
Net Income (Loss) Available to Common Stockholders, Basic											$ 503,000,000
Earnings Per Share, Basic		$ 450,000	$ 0				$ 450,000				$ 2.85
Earnings Per Share, Diluted			$ 0				$ 450,000				$ 2.84
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest		$ 200,000,000	$ (120,000,000)				$ 80,000,000				$ 442,000,000
Net earnings/(loss)			0				81,000,000
Provision/(benefit) for deferred income taxes							13,000,000				14,000,000
Other assets/accrued liabilities, net — current and non-current			(155,000,000)				(181,000,000)				(448,000,000)
Total liabilities		6,235,000,000	5,505,000,000				6,235,000,000				5,712,000,000	5,712,000,000
Accumulated deficit		619,000,000	538,000,000				619,000,000				538,000,000	538,000,000
Equity, Attributable to Parent		4,912,000,000	4,700,000,000				4,912,000,000				4,795,000,000	4,795,000,000
Restatement Adjustment
Accounting Changes and Error Corrections [Abstract]
Other Accrued Liabilities		26,000,000	26,000,000				26,000,000				26,000,000	26,000,000
Total current liabilities		26,000,000	26,000,000				26,000,000				26,000,000	26,000,000
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Other Accrued Liabilities		26,000,000	26,000,000				26,000,000				26,000,000	26,000,000
Total current liabilities		26,000,000	26,000,000				26,000,000				26,000,000	26,000,000
Total liabilities		21,000,000	21,000,000				21,000,000				21,000,000	21,000,000
Accumulated deficit		(20,000,000)	(20,000,000)				(20,000,000)				(20,000,000)	(20,000,000)
Equity, Attributable to Parent		(20,000,000)	(20,000,000)				(20,000,000)				(20,000,000)	(20,000,000)
Prepaid expenses and other		1,000,000	1,000,000				1,000,000				1,000,000	1,000,000
Assets, Current		1,000,000	1,000,000				1,000,000				1,000,000	1,000,000
Assets		1,000,000	1,000,000				1,000,000				1,000,000	1,000,000
Liabilities and Equity		1,000,000	1,000,000				1,000,000				1,000,000
Net revenue			(7,000,000)				(7,000,000)				(26,000,000)
Gross margin			(7,000,000)				(7,000,000)				(26,000,000)
Operating earnings			(7,000,000)				(7,000,000)				(26,000,000)
Income tax expense(benefit)		1,000,000	(2,000,000)				(1,000,000)				(6,000,000)
Net earnings/(loss)		$ (1,000,000)	$ (5,000,000)				$ (6,000,000)				(20,000,000)
Net Income (Loss) Available to Common Stockholders, Basic											$ (20,000,000)
Earnings Per Share, Basic		$ (10,000)	$ (0.03)				$ (30,000)				$ (0.11)
Earnings Per Share, Diluted			$ (0.03)				$ (30,000)				$ (0.11)
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest		$ (1,000,000)	$ (5,000,000)								$ (20,000,000)
Net earnings/(loss)			(5,000,000)				$ (6,000,000)
Provision/(benefit) for deferred income taxes							(1,000,000)				(5,000,000)
Other assets/accrued liabilities, net — current and non-current			5,000,000				7,000,000				25,000,000
Total liabilities		21,000,000	21,000,000				21,000,000				21,000,000	21,000,000
Accumulated deficit		(20,000,000)	(20,000,000)				(20,000,000)				(20,000,000)	(20,000,000)
Equity, Attributable to Parent		(20,000,000)	(20,000,000)				(20,000,000)				(20,000,000)	(20,000,000)
Revision of Prior Period, Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Deferred Tax Liabilities, Gross		$ (5,000,000)	(5,000,000)				(5,000,000)				(5,000,000)	$ (5,000,000)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest			$ (7,000,000)				$ (7,000,000)				$ (26,000,000)

Revenue from Contract with Cust

Revenue from Contract with Customer (Details) - USD ($) $ in Millions	3 Months Ended						6 Months Ended		9 Months Ended		12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Dec. 31, 2022	Dec. 31, 2021	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2022
Disaggregation of Revenue [Line Items]
Net revenue	$ 1,037		$ 1,015	$ 1,273					$ 3,208	$ 3,515	$ 4,802
Inter-segment revenue elimination	(1)	$ (1)	$ 0	(1)	$ (1)	$ (1)	$ (1)	$ (2)	(2)	(3)
Biologics
Disaggregation of Revenue [Line Items]
Net revenue	475			700					1,578	1,889
PharmaConsumerHealth
Disaggregation of Revenue [Line Items]
Net revenue	563			574					1,632	1,629
Manufacturing & Commercial Product Supply | Biologics
Disaggregation of Revenue [Line Items]
Net revenue	133			200					303	503
Manufacturing & Commercial Product Supply | PharmaConsumerHealth
Disaggregation of Revenue [Line Items]
Net revenue	349			368					1,027	1,042
Development Services | Biologics
Disaggregation of Revenue [Line Items]
Net revenue	342			500					1,275	1,386
Development Services | PharmaConsumerHealth
Disaggregation of Revenue [Line Items]
Net revenue	$ 214			$ 206					$ 605	$ 587

Revenue Recognition Disaggregat

Revenue Recognition Disaggregation of Revenue by type of activity and reporting segment (Details) - USD ($) $ in Millions	3 Months Ended						6 Months Ended		9 Months Ended		12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Dec. 31, 2022	Dec. 31, 2021	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2022
Disaggregation of Revenue [Line Items]
Inter-segment revenue elimination	$ (1)	$ (1)	$ 0	$ (1)	$ (1)	$ (1)	$ (1)	$ (2)	$ (2)	$ (3)
Net revenue	1,037		$ 1,015	$ 1,273					3,208	$ 3,515	$ 4,802
Greater Than One Year Member [Member]
Disaggregation of Revenue [Line Items]
Revenue, Remaining Performance Obligation, Percentage to be recognized over the next six months				21%						21%
Biologics
Disaggregation of Revenue [Line Items]
Net revenue	475			$ 700					1,578	$ 1,889
Biologics | Manufacturing & Commercial Product Supply
Disaggregation of Revenue [Line Items]
Net revenue	133			200					303	503
Biologics | Development Services
Disaggregation of Revenue [Line Items]
Net revenue	342			500					1,275	1,386
PharmaConsumerHealth
Disaggregation of Revenue [Line Items]
Net revenue	563			574					1,632	1,629
PharmaConsumerHealth | Manufacturing & Commercial Product Supply
Disaggregation of Revenue [Line Items]
Net revenue	349			368					1,027	1,042
PharmaConsumerHealth | Development Services
Disaggregation of Revenue [Line Items]
Net revenue	214			206					605	587
Total Catalent before inter-segment revenue elimination
Disaggregation of Revenue [Line Items]
Net revenue	1,038			1,274					3,210	3,518
Total Catalent before inter-segment revenue elimination | Manufacturing & Commercial Product Supply
Disaggregation of Revenue [Line Items]
Net revenue	482			568					1,330	1,545
Total Catalent before inter-segment revenue elimination | Development Services
Disaggregation of Revenue [Line Items]
Net revenue	$ 556			$ 706					$ 1,880	$ 1,973

Revenue Recognition Disaggreg_2

Revenue Recognition Disaggregation of Revenue by Geography (Details) - USD ($) $ in Millions	3 Months Ended			9 Months Ended		12 Months Ended
	Mar. 31, 2023	Sep. 30, 2022	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2022
Disaggregation of Revenue [Line Items]
Elimination of revenue attributable to multiple locations	$ (33)		$ (27)	$ (94)	$ (85)
Net revenue	1,037	$ 1,015	1,273	3,208	3,515	$ 4,802
United States
Disaggregation of Revenue [Line Items]
Net revenue	685		847	2,117	2,270
Europe
Disaggregation of Revenue [Line Items]
Net revenue	306		373	936	1,095
International Other
Disaggregation of Revenue [Line Items]
Net revenue	$ 79		$ 80	$ 249	$ 235

Revenue Recognition Contractual

Revenue Recognition Contractual Liabilities (Details) - USD ($) $ in Millions	9 Months Ended
	Mar. 31, 2023	Jun. 30, 2022
Revenue Recognition and Deferred Revenue [Abstract]
Contract with Customer, Liability	$ 212	$ 220
Contract with Customer, Liability, Revenue Recognized	(120)
Revenue, Remaining Performance Obligation, Amount	$ 342

Revenue Recognition Contractu_2

Revenue Recognition Contractual Assets (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2023	Jun. 30, 2022
Text Block [Abstract]
Contract with Customer, Asset, Purchase	$ 505,000,000	$ 441,000,000
Increase (Decrease) in Contract with Customer, Asset	64,000,000
Increase (Decrease) in Contract with Customer, Asset percent	$ 0.15

Business Combinations Acquisiti

Business Combinations Acquisition Purchase Agreement (Details) - USD ($) $ in Millions		9 Months Ended
	Oct. 01, 2021	Mar. 31, 2023	Mar. 31, 2022
Business Acquisition [Line Items]
Payments to Acquire Businesses, Net of Cash Acquired		$ 474	$ 1,033
Bettera Holdings, LLC
Business Acquisition [Line Items]
Payments to Acquire Businesses, Net of Cash Acquired	$ 1,000

Business Combinations Net Asset

Business Combinations Net Assets Acquired (Details) - USD ($) $ in Millions			9 Months Ended
	Oct. 01, 2022	Oct. 01, 2021	Mar. 31, 2023	Mar. 31, 2022
Net Assets Acquired from Business Combinations
Payments to Acquire Businesses, Net of Cash Acquired			$ 474	$ 1,033
Goodwill, Acquired During Period			216
Payments to Acquire Businesses, Net of Cash Acquired			$ 474	$ 1,033
Bettera Holdings, LLC
Net Assets Acquired from Business Combinations
Payments to Acquire Businesses, Net of Cash Acquired		$ 1,000
Payments to Acquire Businesses, Net of Cash Acquired		$ 1,000
Metrics
Net Assets Acquired from Business Combinations
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment	$ 195
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	52
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables	15
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net	474
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory	5
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities	9
Business Combination, Consideration Transferred	474
Goodwill, Acquired During Period	216
Metrics | Customer Relationships [Member]
Net Assets Acquired from Business Combinations
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	$ 52

Business Combinations, Divestit

Business Combinations, Divestitures (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Business Acquisition, Contingent Consideration [Line Items]
Payments for (Proceeds from) Businesses and Interest in Affiliates	[1]	$ 0	$ 0	$ 0	$ 1
Goodwill, Acquired During Period				$ 216
[1]Gain on sale of subsidiary for the nine months ended March 31, 2022

Goodwill - Rollforward (Detail)

Goodwill - Rollforward (Detail) - USD ($) $ in Millions	3 Months Ended						6 Months Ended		9 Months Ended		12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Dec. 31, 2022	Dec. 31, 2021	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2022
Goodwill [Roll Forward]
Beginning balance			$ 3,006				$ 3,006		$ 3,006
Goodwill, Acquired During Period									216
Goodwill, Transfers									0
Foreign currency translation adjustments									11
Ending balance	$ 3,023								$ 3,023		$ 3,006
Goodwill Input, Discount Rate Minimum, Percentage	10.50%								10.50%
Net revenue	$ 1,037		1,015	$ 1,273					$ 3,208	$ 3,515	4,802
Inter-segment revenue elimination	$ (1)	$ (1)	0	(1)	$ (1)	$ (1)	(1)	$ (2)	$ (2)	(3)
Goodwill Inputs Long Term Revenue Growth Rate, Percentage	3%								3%
Goodwill Input, Discount Rate Minimum, Percentage	10.50%								10.50%
Goodwill Input Discount Rate Minimum, Percentage	9%								9%
Goodwill, Impairment Loss	$ (210)			0					$ (210)	0
Biologics
Goodwill [Roll Forward]
Beginning balance			1,535				1,535		1,535
Goodwill, Acquired During Period									0
Goodwill, Transfers									16
Foreign currency translation adjustments									7
Ending balance	1,558								1,558		1,535
Net revenue	475			700					1,578	1,889
Biologics | Manufacturing & Commercial Product Supply
Goodwill [Roll Forward]
Net revenue	133			200					303	503
Biologics | Development Services
Goodwill [Roll Forward]
Net revenue	342			500					1,275	1,386
PharmaConsumerHealth
Goodwill [Roll Forward]
Beginning balance			$ 1,471				$ 1,471		1,471
Goodwill, Acquired During Period									216
Goodwill, Transfers									(16)
Foreign currency translation adjustments									4
Ending balance	1,465								1,465		$ 1,471
Net revenue	563			574					1,632	1,629
Goodwill, Impairment Loss	(210)			0					(210)	0
PharmaConsumerHealth | Manufacturing & Commercial Product Supply
Goodwill [Roll Forward]
Net revenue	349			368					1,027	1,042
PharmaConsumerHealth | Development Services
Goodwill [Roll Forward]
Net revenue	214			206					605	587
Total Catalent before inter-segment revenue elimination
Goodwill [Roll Forward]
Net revenue	1,038			1,274					3,210	3,518
Total Catalent before inter-segment revenue elimination | Manufacturing & Commercial Product Supply
Goodwill [Roll Forward]
Net revenue	482			568					1,330	1,545
Total Catalent before inter-segment revenue elimination | Development Services
Goodwill [Roll Forward]
Net revenue	$ 556			$ 706					$ 1,880	$ 1,973

Other Intangibles, Net (Detail)

Other Intangibles, Net (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Intangible Assets Disclosure [Abstract]
Amortization expense	$ 34	$ 33	$ 101	$ 90

Long-Term Obligations and Oth_2

Long-Term Obligations and Other Short-Term Borrowings - Long-Term Obligations, Presented Net of Issue Discounts and Fees Paid to Lenders, and Other Short-Term Borrowings (Detail) - USD ($) $ in Millions		3 Months Ended	9 Months Ended
		Mar. 31, 2023	Mar. 31, 2023	Jun. 30, 2022
Schedule Of Debt [Line Items]
Total long-term debt		$ 4,849	$ 4,849	$ 4,202
Debt, Current		588	588	31
Long-term obligations, less current portion		4,261	4,261	4,171
Line of Credit, Current		715	715
Debt Instrument, Unused Borrowing Capacity, Amount		546	546
Letters of Credit Outstanding, Amount		4	4
Repayments of Lines of Credit		165
Sale and Leaseback Transaction, Gain (Loss), Net		24
Term loan facility B-3 U.S. dollar-denominated
Schedule Of Debt [Line Items]
Total long-term debt		$ 1,422	$ 1,422	1,433
Debt Instrument, Basis Spread on Variable Rate		1.75%	2.25%
Term loan facility B-3 U.S. dollar-denominated | Minimum [Member]
Schedule Of Debt [Line Items]
Debt Instrument, Basis Spread on Variable Rate			0.75%
Revolving Credit Facility - Two
Schedule Of Debt [Line Items]
Total long-term debt		$ 550	$ 550	0
U.S Dollar-denominated 5.00% Senior Notes [Member]
Schedule Of Debt [Line Items]
Total long-term debt		$ 500	$ 500
Debt Instrument, Interest Rate, Stated Percentage		5%	5%
Capital lease obligations
Schedule Of Debt [Line Items]
Total long-term debt		$ 297	$ 297	234
Other obligations
Schedule Of Debt [Line Items]
Total long-term debt		26	26	2
Estimate of Fair Value Measurement [Member]
Schedule Of Debt [Line Items]
Total long-term debt		4,493	4,493	3,839
Debt Instrument, Fair Value Disclosure		4,493	4,493	3,839
Estimate of Fair Value Measurement [Member] | Debt Issuance Costs
Schedule Of Debt [Line Items]
Total long-term debt		0	0	0
Carrying Value [Member]
Schedule Of Debt [Line Items]
Total long-term debt		4,849	4,849	4,202
Debt Instrument, Fair Value Disclosure		4,890	4,890	4,243
Carrying Value [Member] | Debt Issuance Costs
Schedule Of Debt [Line Items]
Total long-term debt		41	41	41
Fair Value, Inputs, Level 2 [Member] | Estimate of Fair Value Measurement [Member] | U.S Dollar-denominated 5.00% Senior Notes [Member]
Schedule Of Debt [Line Items]
Debt Instrument, Fair Value Disclosure		493	493	483
Fair Value, Inputs, Level 2 [Member] | Estimate of Fair Value Measurement [Member] | 2.375% Senior Euro Denominated Notes [Member]
Schedule Of Debt [Line Items]
Debt Instrument, Fair Value Disclosure		823	823	744
Fair Value, Inputs, Level 2 [Member] | Estimate of Fair Value Measurement [Member] | 3.125% Senior US Denominated Notes
Schedule Of Debt [Line Items]
Debt Instrument, Fair Value Disclosure		500	500	476
Fair Value, Inputs, Level 2 [Member] | Estimate of Fair Value Measurement [Member] | 3.500% Senior US Denominated Notes
Schedule Of Debt [Line Items]
Debt Instrument, Fair Value Disclosure		598	598	561
Fair Value, Inputs, Level 2 [Member] | Carrying Value [Member] | U.S Dollar-denominated 5.00% Senior Notes [Member]
Schedule Of Debt [Line Items]
Debt Instrument, Fair Value Disclosure		500	500	500
Fair Value, Inputs, Level 2 [Member] | Carrying Value [Member] | 2.375% Senior Euro Denominated Notes [Member]
Schedule Of Debt [Line Items]
Debt Instrument, Fair Value Disclosure	[1]	895	895	874
Fair Value, Inputs, Level 2 [Member] | Carrying Value [Member] | 3.125% Senior US Denominated Notes
Schedule Of Debt [Line Items]
Debt Instrument, Fair Value Disclosure		550	550	550
Fair Value, Inputs, Level 2 [Member] | Carrying Value [Member] | 3.500% Senior US Denominated Notes
Schedule Of Debt [Line Items]
Debt Instrument, Fair Value Disclosure		$ 650	$ 650	$ 650
[1]The change in the carrying value of this euro-denominated debt was due to fluctuations in foreign currency exchange rates.(3)    The increase in other obligations is associated with $24 million in proceeds from a failed sale-leaseback transaction that occurred in the three months ended March 31, 2023.

Long-Term Obligations and Oth_3

Long-Term Obligations and Other Short-Term Borrowings Long-Term Obligations and Other Short-Term Borrowings (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Mar. 31, 2023	Mar. 31, 2023	Jun. 30, 2022
Debt Instrument [Line Items]
Total long-term debt	$ 4,849	$ 4,849	$ 4,202
Other Short-Term Borrowings	550	550
U.S Dollar-denominated 5.00% Senior Notes [Member]
Debt Instrument [Line Items]
Total long-term debt	$ 500	$ 500
Debt Instrument, Interest Rate, Stated Percentage	5%	5%
Term loan facility B-3 U.S. dollar-denominated
Debt Instrument [Line Items]
Total long-term debt	$ 1,422	$ 1,422	1,433
Debt Instrument, Basis Spread on Variable Rate	1.75%	2.25%
Term loan facility B-3 U.S. dollar-denominated | Minimum [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate		0.75%
Term loan facility B-3 U.S. dollar-denominated | Maximum [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate		1.25%
Revolving Credit Facility - Two
Debt Instrument [Line Items]
Total long-term debt	$ 550	$ 550	$ 0
Revolving Credit Commitments
Debt Instrument [Line Items]
Total long-term debt	$ 1,100	$ 1,100

Long-Term Obligations and Oth_4

Long-Term Obligations and Other Short-Term Borrowings Fair Value Measurements of Financial Instruments - Carrying Amounts and Estimated Fair Value of Financial Instruments (Details) - USD ($) $ in Millions		Mar. 31, 2023	Jun. 30, 2022
Fair Value Measurements Of Financial Instruments [Line Items]
Total long-term debt		$ 4,849	$ 4,202
Estimate of Fair Value Measurement [Member]
Fair Value Measurements Of Financial Instruments [Line Items]
Debt Instrument, Fair Value Disclosure		4,493	3,839
Total long-term debt		4,493	3,839
Carrying Value [Member]
Fair Value Measurements Of Financial Instruments [Line Items]
Debt Instrument, Fair Value Disclosure		4,890	4,243
Total long-term debt		4,849	4,202
Term loan facility B-3 U.S. dollar-denominated
Fair Value Measurements Of Financial Instruments [Line Items]
Total long-term debt		$ 1,422	1,433
U.S Dollar-denominated 5.00% Senior Notes [Member]
Fair Value Measurements Of Financial Instruments [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		5%
Total long-term debt		$ 500
U.S Dollar-denominated 5.00% Senior Notes [Member] | Fair Value, Inputs, Level 2 [Member] | Estimate of Fair Value Measurement [Member]
Fair Value Measurements Of Financial Instruments [Line Items]
Debt Instrument, Fair Value Disclosure		493	483
U.S Dollar-denominated 5.00% Senior Notes [Member] | Fair Value, Inputs, Level 2 [Member] | Carrying Value [Member]
Fair Value Measurements Of Financial Instruments [Line Items]
Debt Instrument, Fair Value Disclosure		500	500
2.375% Senior Euro Denominated Notes [Member] | Fair Value, Inputs, Level 2 [Member] | Estimate of Fair Value Measurement [Member]
Fair Value Measurements Of Financial Instruments [Line Items]
Debt Instrument, Fair Value Disclosure		823	744
2.375% Senior Euro Denominated Notes [Member] | Fair Value, Inputs, Level 2 [Member] | Carrying Value [Member]
Fair Value Measurements Of Financial Instruments [Line Items]
Debt Instrument, Fair Value Disclosure	[1]	895	874
3.125% Senior US Denominated Notes | Fair Value, Inputs, Level 2 [Member] | Estimate of Fair Value Measurement [Member]
Fair Value Measurements Of Financial Instruments [Line Items]
Debt Instrument, Fair Value Disclosure		500	476
3.125% Senior US Denominated Notes | Fair Value, Inputs, Level 2 [Member] | Carrying Value [Member]
Fair Value Measurements Of Financial Instruments [Line Items]
Debt Instrument, Fair Value Disclosure		550	550
Senior Secured Credit Facilities & Other [Member] | Fair Value, Inputs, Level 2 [Member] | Estimate of Fair Value Measurement [Member]
Fair Value Measurements Of Financial Instruments [Line Items]
Debt Instrument, Fair Value Disclosure		2,079	1,575
Senior Secured Credit Facilities & Other [Member] | Fair Value, Inputs, Level 2 [Member] | Carrying Value [Member]
Fair Value Measurements Of Financial Instruments [Line Items]
Debt Instrument, Fair Value Disclosure		$ 2,295	$ 1,669
[1]The change in the carrying value of this euro-denominated debt was due to fluctuations in foreign currency exchange rates.(3)    The increase in other obligations is associated with $24 million in proceeds from a failed sale-leaseback transaction that occurred in the three months ended March 31, 2023.

Earnings Per Share Earnings Per

Earnings Per Share Earnings Per Share - Additional Details (Details) - USD ($) $ / shares in Units, $ in Millions	Nov. 18, 2021	Nov. 23, 2020	Mar. 31, 2023	Jun. 30, 2022
Earnings Per Share [Abstract]
Conversion of Stock, Shares Converted	384,777	265,223
Dividends, Preferred Stock, Stock	$ 2	$ 2
Common Stock, Par or Stated Value Per Share			$ 0.01	$ 0.01

Earnings Per Share (Details)

Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended				9 Months Ended		12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2022
Earnings Per Share [Abstract]
Net earnings/(loss)	$ (227)	$ 80	$ (5)	$ 141	$ (146)	$ 331	$ 499
Participating Securities, Distributed and Undistributed Earnings (Loss), Basic	0			0	0	15
Net Income (Loss) Available to Common Stockholders, Basic	$ (227)			$ 141	$ (146)	$ 316	$ 483
Weighted Average Number of Shares Outstanding, Basic	181			180	180	176
Dilutive securities issuable-stock plans	0			1	0	1
Total weighted average diluted shares outstanding	181			181	180	177
Earnings Per Share, Basic	$ (1.26)	$ 440,000	$ (0.03)	$ 0.78	$ (0.81)	$ 1.81	$ 2.74
Earnings Per Share, Diluted	$ (1.26)		$ (0.03)	$ 0.78	$ (0.81)	$ 1.79	$ 2.73

Other Income and Expense (Detai

Other Income and Expense (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Other Income and Expenses [Abstract]
Debt refinancing costs	[1]	—	—	—	4
Foreign Currency (gains) and losses	[2]	$ (4)	$ 4	$ (5)	$ 28
Other	[3]	0	(2)	3	(7)
Other (income)/expense, net	[4]	(4)	$ 2	(2)	25
Gain (Loss) on Extinguishment of Debt				4
Term Loan Facility Incremental Dollar Term B-3		$ 450
Derivative, Gain (Loss) on Derivative, Net				$ 0	$ 2
[1]Debt financing costs for the nine months ended March 31, 2022 includes $4 million of financing charges related to the $450 million aggregate principal amount of U.S. dollar-denominated term loans borrowed in that period under the Company’s senior secured credit facilities (together with all of the remaining U.S. dollar-denominated term loans outstanding, the “Term B-3 Loans”).

Restructuring and Other Costs (

Restructuring and Other Costs (Details) $ in Millions	3 Months Ended		9 Months Ended
	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)	Mar. 31, 2023 USD ($) employees	Mar. 31, 2022 USD ($)
Restructuring and Related Activities [Abstract]
Severance Costs	$ 4	$ 3	$ 18	$ 5
Business Exit Costs	5		18
Restructuring and other	9	3	36	5
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	18		$ 18
Restructuring and Related Cost [Abstract]
Restructuring and Related Cost, Number of Positions Eliminated | employees			700
Restructuring and other	9	3	$ 36	5
Biologics
Restructuring and Related Activities [Abstract]
Restructuring and other	7	1	25	1
Restructuring and Related Cost [Abstract]
Restructuring and other	7	1	25	1
PharmaConsumerHealth
Restructuring and Related Activities [Abstract]
Restructuring and other	1	1	5	3
Restructuring and Related Cost [Abstract]
Restructuring and other	1	1	5	3
Corporate and Eliminations [Member]
Restructuring and Related Activities [Abstract]
Restructuring and other	1	1	6	1
Restructuring and Related Cost [Abstract]
Restructuring and other	$ 1	$ 1	$ 6	$ 1

Restructuring and Other Costs I

Restructuring and Other Costs Individual Site (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	$ 18		$ 18
Restructuring and other	$ 9	$ 3	$ 36	$ 5

Derivative Instruments and He_3

Derivative Instruments and Hedging Activities - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2022
Derivative [Line Items]
Total long-term debt	$ 4,849		$ 4,849		$ 4,202
Unrealized foreign exchange gain/(loss) within other comprehensive income	(16)	$ 28	(20)	$ 90
Unrealized foreign exchange gain/(loss) within statement of operations	0	$ 0	0	(11)
Net accumulated gain related to investment hedges			107
Derivative, Gain (Loss) on Derivative, Net			0	$ 2
Cash Paid to Settle, Interest Rate Swap Agreement	2		2
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax	15
Interest Rate Cash Flow Hedge Liability at Fair Value					36
Carrying Value [Member]
Derivative [Line Items]
Total long-term debt	4,849		4,849		4,202
Debt Instrument, Fair Value Disclosure	4,890		4,890		4,243
Euro Denominated Debt Outstanding [Member]
Derivative [Line Items]
Total long-term debt	895		895
U.S. Denominated Term Loan [Member]
Derivative [Line Items]
Total Debt, U.S Denominated Term Loan	$ 500		$ 500
Debt Instrument, Interest Rate, Effective Percentage	0.9985%		0.9985%
3.500% Senior US Denominated Notes | Fair Value, Inputs, Level 2 [Member] | Carrying Value [Member]
Derivative [Line Items]
Debt Instrument, Fair Value Disclosure	$ 650		$ 650		$ 650

Fair value measurement recurrin

Fair value measurement recurring basis (Detail) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Marketable Securities		$ 0		$ 0		$ 89
Trading Securities at Fair Value		1		1		2
Interest Rate Cash Flow Hedge Asset at Fair Value		51		51		36
Interest Rate Cash Flow Hedge Liability at Fair Value						36
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Marketable Securities		0		0		89
Trading Securities at Fair Value		1		1		2
Interest Rate Cash Flow Hedge Asset at Fair Value		51		51		36
Interest Rate Cash Flow Hedge Liability at Fair Value						36
Payments for (Proceeds from) Businesses and Interest in Affiliates	[1]	0	$ 0	0	$ 1
Derivative, Gain (Loss) on Derivative, Net				0	$ 2
Fair Value, Inputs, Level 1 [Member]
Fair Value Disclosures [Abstract]
Marketable Securities						89
Trading Securities at Fair Value		1		1		2
Interest Rate Cash Flow Hedge Asset at Fair Value		0		0		0
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Marketable Securities						89
Trading Securities at Fair Value		1		1		2
Interest Rate Cash Flow Hedge Asset at Fair Value		0		0		0
Fair Value, Inputs, Level 2 [Member]
Fair Value Disclosures [Abstract]
Marketable Securities						0
Trading Securities at Fair Value		0		0		0
Interest Rate Cash Flow Hedge Asset at Fair Value		51		51		36
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Marketable Securities						0
Trading Securities at Fair Value		0		0		0
Interest Rate Cash Flow Hedge Asset at Fair Value		51		51		36
Fair Value, Inputs, Level 3 [Member]
Fair Value Disclosures [Abstract]
Marketable Securities						0
Trading Securities at Fair Value		0		0		0
Interest Rate Cash Flow Hedge Asset at Fair Value		0		0		0
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Marketable Securities						0
Trading Securities at Fair Value		0		0		0
Interest Rate Cash Flow Hedge Asset at Fair Value		$ 0		$ 0		$ 0
[1]Gain on sale of subsidiary for the nine months ended March 31, 2022

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended				9 Months Ended		12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Unrecognized Tax Benefits, Including Income Tax Penalties and Interest Accrued	$ 2				$ 2		$ 5
Income tax expense(benefit)	(55)	$ 34	$ 1	$ 35	(19)	$ 63	80
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$ (282)		$ (4)	$ 176	$ (165)	$ 394	$ 579

Employee Retirement Benefit P_3

Employee Retirement Benefit Plans - Components of Company's Net Periodic Benefit Costs (Detail) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Components of net periodic benefit cost:
Service cost		$ 1	$ 1	$ 3	$ 3
Interest cost		3	1	7	3
Expected return on plan assets		(2)	(2)	(6)	(7)
Amortization	[1]	0	1	0	3
Net amount recognized		2	1	4	2
Estimated discounted value of future employer contributions		38		38
Estimated annual cash contribution		$ 2	$ 2	$ 2	$ 2
[1]Amount represents the amortization of unrecognized actuarial losses.

Equity and Accumulated Other _3

Equity and Accumulated Other Comprehensive Income (Loss) - Equity (Details) - USD ($) $ / shares in Units, $ in Millions			9 Months Ended
	Nov. 18, 2021	Nov. 23, 2020	Mar. 31, 2022	Mar. 31, 2023	Jun. 30, 2022	May 17, 2019
Equity [Abstract]
Common Stock, Shares Authorized				1,000,000,000	1,000,000,000
Preferred Stock, Shares Authorized				100,000,000	100,000,000
Conversion of Stock, Shares Converted	384,777	265,223
Dividends, Preferred Stock, Stock	$ 2	$ 2
Preferred Stock, Shares Outstanding				0	0
Stock Issued During Period, Value, Conversion of Convertible Securities			$ (362)
Auction Market Preferred Securities, Stock Series [Line Items]
Preferred Stock, Shares Authorized				100,000,000	100,000,000
Preferred Stock, Par or Stated Value Per Share				$ 0.01	$ 0.01
Preferred Stock, Shares Issued				0	0
Dividends, Preferred Stock, Stock	$ 2	$ 2
Series A [Member]
Auction Market Preferred Securities, Stock Series [Line Items]
Preferred Stock, Shares Issued						650,000

Equity and Accumulated Other _4

Equity and Accumulated Other Comprehensive Income (Loss) - Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Foreign currency translation adjustments:
Net investment hedge	$ (16)	$ 28	$ (20)	$ 90
Long-term intercompany loans	9	(8)	(1)	(15)
Translation adjustments	31	(36)	26	(109)
Total foreign currency translation adjustment, pretax	24	(16)	5	(34)
Tax expense/(benefit)	(3)	6	(5)	20
Total foreign currency translation adjustment, net of tax	27	(22)	10	(54)
Net change in derivatives and hedges
Net loss recognized during the period	(3)	23	15	28
Total derivatives and hedges, pretax	(3)	23	15	28
Tax expense/(benefit)	(1)	6	3	7
Net change in derivatives and hedges, net of tax	(2)	17	12	21
Net change in minimum pension liability
Net gain/(loss) recognized during the period	0	1	0	2
Total pension liability, pretax	0	1	0	2
Tax expense/(benefit)	0	0	0	0
Pension and other post-retirement adjustments	0	1	0	2
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent [Abstract]
Available-for-sale Securities, Gross Realized Losses	0	(2)	1	(3)
Total available for sale investment, pretax	2	(2)	5	(3)
Tax expense/(benefit)		1	0	(1)
Available for sale investments	2	(1)	4	(2)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other comprehensive income/(loss) before reclassifications	$ 25	$ (6)	$ 22	$ (35)

Equity and Accumulated Other _5

Equity and Accumulated Other Comprehensive Income (Loss) - Rollforward (Details) - USD ($) $ in Millions	3 Months Ended			9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2023	Mar. 31, 2022
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning Balance	$ (395)	$ (345)		$ (394)	$ (317)
Other comprehensive income/(loss) before reclassifications	25	(6)		22	(35)
Amounts reclassified from accumulated other comprehensive income/(loss)	2	(1)		4	2
Total foreign currency translation adjustment, net of tax	27	(22)		10	(54)
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax	0	1		0	2
Net change in derivatives and hedges, net of tax	(2)	17		12	21
Other Comprehensive Income, Other, Net of Tax	27	(5)		26	(33)
Available for sale investments	2	(1)		4	(2)
Other comprehensive income/(loss), net of tax	27	(5)		26	(33)
Ending Balance	(368)	(350)		(368)	(350)
Accumulated Translation Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning Balance	(395)	(300)		(378)	(268)
Other comprehensive income/(loss) before reclassifications	27	(22)		10	(54)
Amounts reclassified from accumulated other comprehensive income/(loss)	0
Total foreign currency translation adjustment, net of tax		(22)		10	(54)
Ending Balance	(368)	(322)		(368)	(322)
Accumulated Defined Benefit Plans Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning Balance	(38)	(46)		(38)	(47)
Other comprehensive income/(loss) before reclassifications	0
Amounts reclassified from accumulated other comprehensive income/(loss)	0	1			2
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax	0	1		0	2
Ending Balance	(38)	(45)		(38)	(45)
AOCI, Derivative Qualifying as Hedge, Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning Balance	41	4		27
Other comprehensive income/(loss) before reclassifications	(2)	17		12	21
Amounts reclassified from accumulated other comprehensive income/(loss)	0
Ending Balance	39	21		39	21
ACOI, Accumulated Gain (Loss), Marketable Securities [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning Balance	(2)	(2)		(4)	(1)
Other comprehensive income/(loss) before reclassifications	0	(1)	$ 0		(2)
Amounts reclassified from accumulated other comprehensive income/(loss)	2			4
Net change in derivatives and hedges, net of tax	(2)	17		12	21
Available for sale investments		(1)		4	(2)
Ending Balance	0	(3)		0	(3)
Available-for-sale Securities [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning Balance	(1)	(1)		(1)	(1)
Other comprehensive income/(loss) before reclassifications	0
Amounts reclassified from accumulated other comprehensive income/(loss)	0
Other Comprehensive Income, Other, Net of Tax	0
Ending Balance	$ (1)	$ (1)		$ (1)	$ (1)

Segment Information - Net Reven

Segment Information - Net Revenue and Segment Ebitda (Detail) - USD ($) $ in Millions		3 Months Ended						6 Months Ended		9 Months Ended		12 Months Ended
		Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Dec. 31, 2022	Dec. 31, 2021	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2022
Segment Reporting, Revenue & EBITDA Reconciling Item [Line Items]
Net revenue		$ 1,037		$ 1,015	$ 1,273					$ 3,208	$ 3,515	$ 4,802
Inter-segment revenue elimination		(1)	$ (1)	$ 0	(1)	$ (1)	$ (1)	$ (1)	$ (2)	(2)	(3)
Segment Reporting Information Unallocated Expense	[1]	(256)			(54)					(394)	(211)
Biologics
Segment Reporting, Revenue & EBITDA Reconciling Item [Line Items]
Net revenue		475			700					1,578	1,889
Segment EBITDA		6			218					299	584
PharmaConsumerHealth
Segment Reporting, Revenue & EBITDA Reconciling Item [Line Items]
Net revenue		563			574					1,632	1,629
Segment EBITDA		125			144					368	390
Total Catalent sub-total of Segment Reporting [Member]
Segment Reporting, Revenue & EBITDA Reconciling Item [Line Items]
Segment EBITDA		$ 131			$ 362					$ 667	$ 974
[1]Unallocated costs include restructuring and special items, stock-based compensation, gain on sale of subsidiary, impairment charges, certain other corporate directed costs, and other costs that are not allocated to the segments as follows:

Segment Information, EBITDA, Re

Segment Information, EBITDA, Reconciling Items (Detail) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Unallocated costs [Abstract]
Impairment Charges And Gain Loss On Sale Of Assets		$ 6	$ 2	$ 4	$ 21
Stock-based compensation		6	10	35	42
Restructuring And Other Special Items	[1]	17	12	59	43
Payments for (Proceeds from) Businesses and Interest in Affiliates	[2]	0	0	0	1
Other (income)/expense, net	[3]	4	(2)	2	(25)
Non Allocated Corporate Costs Net		21	28	88	81
Segment Reporting Information Unallocated Expense	[4]	256	54	394	211
Goodwill, Impairment Loss		$ (210)	$ 0	$ (210)	$ 0
[1]Restructuring and other special items during the three months ended March 31, 2023 include (i) restructuring charges associated with plans to reduce costs, consolidate facilities, and optimize our infrastructure across the organization and (ii) transaction and integration costs associated with the Metrics acquisition. Restructuring and other special items for the nine months ended March 31, 2023 also includes warehouse exit costs for a product the Company no longer manufactures in its Pharma and Consumer Health segment. For further details on restructuring charges, see Note 9, Restructuring Costs . Restructuring and other special items during the three months ended March 31, 2022 include (i) integration costs primarily associated with the Bettera Wellness acquisition and (ii) unrealized losses on venture capital investments. Restructuring and other special items during the nine months ended March 31, 2022 also include transaction and integration costs associated with the Delphi Genetics S.A., Hepatic Cell Therapy Support S.A., RheinCell Therapeutics GmbH acquisitions and the Acorda Therapeutics, Inc. transaction. (c) Goodwill impairment charges during the three and nine months ended March 31, 2023 was associated with the Company’s Consumer Health reporting unit. For further details, see Note 5, Goodwill .

Segment Information - Reconcili

Segment Information - Reconciliation of Earnings / (Loss) from Continuing Operations to Ebitda (Detail) - USD ($) $ in Millions		3 Months Ended				9 Months Ended		12 Months Ended
		Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2022
Segment Reporting [Abstract]
Segment Reporting Information Unallocated Expense	[1]	$ 256			$ 54	$ 394	$ 211
Depreciation and amortization		106			99	308	278
Interest expense, net		51			33	130	91
Income tax expense(benefit)		(55)	$ 34	$ 1	35	(19)	63	$ 80
Earnings/(loss) from continuing operations		$ (227)			$ 141	$ (146)	$ 331
[1]Unallocated costs include restructuring and special items, stock-based compensation, gain on sale of subsidiary, impairment charges, certain other corporate directed costs, and other costs that are not allocated to the segments as follows:

Segment Information - Total Ass

Segment Information - Total Assets for Each Segment and Reconciling in Consolidated Financial Statements (Detail) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets		$ 10,830		$ 10,830		$ 10,508	$ 11,148	$ 10,206	$ 10,508
Payments for (Proceeds from) Businesses and Interest in Affiliates	[1]	0	$ 0	0	$ 1
Biologics
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets		5,904		5,904					5,770
PharmaConsumerHealth
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets		4,847		4,847					4,356
Corporate and Eliminations [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets		$ 79		$ 79					$ 382
[1]Gain on sale of subsidiary for the nine months ended March 31, 2022

Segment Information - Major Cus

Segment Information - Major Customers (Details)	9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Segment Reporting [Abstract]
Segment Reporting, Disclosure of Major Customers	11	9

Supplemental Balance Sheet In_3

Supplemental Balance Sheet Information - Inventory (Detail) - USD ($) $ in Millions	Mar. 31, 2023	Jun. 30, 2022
Inventory, Net [Abstract]
Raw materials and supplies	$ 762	$ 651
Work-in-process	144	109
Total inventories, gross	906	760
Inventory cost adjustment	(162)	(58)
Inventories	$ 744	$ 702

Supplemental Balance Sheet In_4

Supplemental Balance Sheet Information - Prepaid and Other Assets (Detail) - USD ($) $ in Millions	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid expenses		$ 70			$ 61
Contract with Customer, Asset, Net, Current		488			398
Spare parts supplies		24			22
Prepaid income tax		35			27
Non-U.S. value added tax		35			48
Other current assets		41			70
Prepaid expenses and other	$ 626	$ 693	$ 715	$ 633	$ 626

Supplemental Balance Sheet In_5

Supplemental Balance Sheet Information - Other Accrued Liabilities (Detail) - USD ($) $ in Millions	Mar. 31, 2023	Jun. 30, 2022
Balance Sheet Related Disclosures [Abstract]
Accrued employee-related expenses	$ 132	$ 198
Accrued Operating Lease, Liabilities	11	14
Restructuring accrual	1	1
Accrued interest	24	32
Contract liability	203	211
Accrued income tax	23	50
Other accrued liabilities and expenses	111	140
Other accrued liabilities	$ 505	$ 646

Subsequent Events (Details)

Subsequent Events (Details) - USD ($) $ in Millions		3 Months Ended			9 Months Ended
	Oct. 01, 2022	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021
Subsequent Event
Unrecognized Tax Benefits, Including Income Tax Penalties and Interest Accrued		$ 2			$ 2					$ 5
Assets		10,830			10,830		$ 10,508	$ 11,148	$ 10,206	10,508
Line of Credit, Current		715			715
Other comprehensive income/(loss) before reclassifications		25	$ (6)		22	$ (35)
Foreign currency translation adjustments		27	(22)		10	(54)
Net change in derivatives and hedges, net of tax		(2)	17		12	21
Available for sale investments		2	(1)		4	(2)
Other Comprehensive Income, Other, Net of Tax		27	(5)		26	(33)
Accumulated other comprehensive income/(loss)		(368)	(350)		(368)	(350)		(395)		(394)	$ (345)	$ (317)
Amounts reclassified from accumulated other comprehensive income/(loss)		2	(1)		4	2
Pension and other post-retirement adjustments		0	1		0	2
Tax expense/(benefit)			1		0	(1)
Accumulated Translation Adjustment [Member]
Subsequent Event
Other comprehensive income/(loss) before reclassifications		27	(22)		10	(54)
Foreign currency translation adjustments			(22)		10	(54)
Accumulated other comprehensive income/(loss)		(368)	(322)		(368)	(322)		(395)		(378)	(300)	(268)
Amounts reclassified from accumulated other comprehensive income/(loss)		0
AOCI, Derivative Qualifying as Hedge, Parent [Member]
Subsequent Event
Other comprehensive income/(loss) before reclassifications		(2)	17		12	21
Accumulated other comprehensive income/(loss)		39	21		39	21		41		27	4
Amounts reclassified from accumulated other comprehensive income/(loss)		0
ACOI, Accumulated Gain (Loss), Marketable Securities [Member]
Subsequent Event
Other comprehensive income/(loss) before reclassifications		0	(1)	$ 0		(2)
Net change in derivatives and hedges, net of tax		(2)	17		12	21
Available for sale investments			(1)		4	(2)
Accumulated other comprehensive income/(loss)		0	(3)		0	(3)		(2)		(4)	(2)	(1)
Amounts reclassified from accumulated other comprehensive income/(loss)		2			4
Accumulated Defined Benefit Plans Adjustment [Member]
Subsequent Event
Other comprehensive income/(loss) before reclassifications		0
Accumulated other comprehensive income/(loss)		(38)	(45)		(38)	(45)		(38)		(38)	(46)	(47)
Amounts reclassified from accumulated other comprehensive income/(loss)		0	1			2
Pension and other post-retirement adjustments		0	1		0	2
Available-for-sale Securities [Member]
Subsequent Event
Other comprehensive income/(loss) before reclassifications		0
Other Comprehensive Income, Other, Net of Tax		0
Accumulated other comprehensive income/(loss)		(1)	(1)		(1)	(1)		$ (1)		(1)	$ (1)	$ (1)
Amounts reclassified from accumulated other comprehensive income/(loss)		0
PharmaConsumerHealth
Subsequent Event
Segment EBITDA		125	$ 144		368	$ 390
Assets		$ 4,847			$ 4,847					$ 4,356
Metrics
Subsequent Event
Business Combination, Consideration Transferred	$ 474